

ATAZANAVIR VIATRIS

1. Product Name

Atazanavir Viatriis 150 mg capsules

Atazanavir Viatriis 200 mg capsules

Atazanavir Viatriis 300 mg capsules

2. Qualitative and Quantitative Composition

Atazanavir Viatriis 150 mg: each capsule contains 150 mg of atazanavir (as sulfate).

Atazanavir Viatriis 200 mg: each capsule contains 200 mg of atazanavir (as sulfate).

Atazanavir Viatriis 300 mg: each capsule contains 300 mg of atazanavir (as sulfate).

Excipient with known effect: Lactose

Allergen declaration: Sugars as lactose.

For a full list of excipients, see section 6.1

3. Pharmaceutical Form

Hard gelatin capsules.

Atazanavir Viatriis 150 mg capsules: No.1, greenish-blue opaque cap and blue opaque body, hard-shell gelatin capsule filled with white to pale yellow powder. The capsule is axially printed with MYLAN over AR150 in black ink on both the cap and body.

Atazanavir Viatriis 200 mg capsules: No.0, blue opaque cap and greenish-blue opaque body, hard-shell gelatin capsule filled with white to pale yellow powder. The capsule is axially printed with MYLAN over AR200 in black ink on both the cap and body.

Atazanavir Viatriis 300 mg capsules: No.00, red opaque cap and greenish-blue opaque body, hard-shell gelatin capsule filled with white to pale yellow powder. The capsule is axially printed with MYLAN over AR300 in black ink on both the cap and body.

4. Clinical Particulars

4.1 *Therapeutic indications*

Atazanavir Viatriis is indicated for the treatment of HIV 1 infection, in combination with other antiretroviral agents in adult patients and in paediatric patients 6 to 18 years of age.

This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies (see section 5.1).

4.2 Dose and method of administration

General dosing recommendations

Atazanavir Viatris capsules must be taken with food.

Atazanavir Viatris capsules should be taken WHOLE. The recommended doses are to be administered using combinations of registered capsule strengths; e.g. a dose of 300 mg may be administered as one 300 mg capsule or two 150 mg capsules.

The recommended oral dosage of atazanavir depends on the treatment history of the patient and the use of other co-administered medicines.

When co-administered with didanosine buffered or enteric-coated formulations atazanavir should be given (with food) 2 hours before or 1 hour after didanosine.

Atazanavir Viatris without ritonavir is not recommended for treatment-experienced patients with prior virologic failure.

Efficacy and safety of atazanavir with ritonavir in doses greater than 100 mg once daily have not been established. The use of higher ritonavir doses might alter the safety profile of atazanavir and therefore is not recommended. Prescribers should consult the complete prescribing information for ritonavir when using this agent.

For further information refer to sections 4.3, 4.4 and 5.2.

Dose recommendations for therapy-naïve adult patients

Atazanavir Viatris 400 mg once daily

Or

Atazanavir Viatris 300 mg with ritonavir 100 mg once daily.

Concomitant therapy

Atazanavir Viatris without ritonavir is not recommended when co-administered with the medicines listed below. Atazanavir Viatris 300 mg with ritonavir 100 mg should be administered with any of the following:

- Tenofovir (disoproxil fumarate)
- Efavirenz: Co-administration of Atazanavir Viatris with efavirenz is not recommended. If the combination of Atazanavir Viatris and efavirenz is judged to be unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of Atazanavir Viatris to 400 mg with 100 mg of ritonavir both administered as a single dose with food and efavirenz administered on an empty stomach, preferably at bedtime.
- H₂-receptor antagonist: The H₂-receptor antagonist dose should not exceed a 40 mg dose equivalent of famotidine twice daily. Atazanavir Viatris 300 mg and ritonavir 100 mg should be administered simultaneously with, and/or at least 10 hours after, the dose of the H₂-receptor antagonist.
- Proton-pump inhibitors: The proton-pump inhibitor dose should not exceed a 20 mg dose equivalent of omeprazole and must be taken approximately 12 hours prior to the Atazanavir Viatris 300 mg and ritonavir 100 mg dose.

Dose recommendations for therapy-experienced adult patients

Atazanavir Viatris 300 mg with ritonavir 100 mg once daily.

Atazanavir Viatris without ritonavir is not recommended for treatment experienced patients with prior virologic failure.

Concomitant therapy

- Whenever a H₂-receptor antagonist is given to a patient receiving Atazanavir Viatriis with ritonavir, the H₂-receptor antagonist dose should not exceed a dose equivalent to famotidine 20 mg twice daily, and the Atazanavir Viatriis and ritonavir doses should be administered simultaneously with, and/or at least 10 hours after, the dose of the H₂-receptor antagonist.
- Atazanavir Viatriis 300 mg with ritonavir 100 mg once daily if taken with a H₂-receptor antagonist.
- Atazanavir Viatriis 400 mg with ritonavir 100 mg once daily if taken with both tenofovir and a H₂-receptor antagonist.

Proton-pump inhibitors should not be used in treatment-experienced patients receiving Atazanavir Viatriis.

In treatment-experienced patients, Atazanavir Viatriis should not be co-administered with efavirenz.

Special populations

Paediatric patients (6 – 18 years of age)

The dosage of Atazanavir Viatriis for treatment-naïve and treatment-experienced paediatric patients (6 to 18 years of age) is shown in Table 1 and should not exceed the recommended adult dosage.

Atazanavir Viatriis capsules must be taken with food.

For treatment-naïve patients at least 13 years of age and at least 40 kg, who are unable to tolerate ritonavir, the recommended dose is Atazanavir Viatriis 400 mg (without ritonavir) once daily with food.

Table 1: Paediatric and Adolescent Dose for Atazanavir Viatriis capsules with ritonavir (6 to 18 years of age)^{a,b}

Body Weight ^c (kg)	Atazanavir Viatriis Dose (mg) ^d	Ritonavir Dose (mg)
15 to less than 35	200	100 ^e
At least 35	300	100 ^e

- a. Dosage recommendations in Table 1 were derived from refined population pharmacokinetic (PopPK) modelling and simulation.
- b. The Atazanavir Viatriis and ritonavir dose should be taken once daily with food.
- c. There are limited or no data in paediatric patients less than 6 years of age and less than 15 kg.
- d. Doses of Atazanavir Viatriis can be achieved using a combination of commercially available capsule strengths.
- e. Ritonavir capsule or liquid

Paediatric patients less than 6 years of age

There are no dosing recommendations for Atazanavir Viatriis in paediatric patients less than 6 years of age. Atazanavir Viatriis should not be administered to paediatric patients below 3 months of age due to the risk of kernicterus.

Patients with renal impairment

For patients with renal impairment, including those with severe renal impairment who are not managed by haemodialysis, no dosage adjustment is required for Atazanavir Viatriis. Treatment-naïve patients with end stage renal disease managed with haemodialysis should receive Atazanavir Viatriis 300 mg with ritonavir 100 mg.

Atazanavir Viatriis should not be administered to HIV-treatment experienced patients with end stage renal disease managed with haemodialysis (see section 5.2).

Atazanavir Viatriis without ritonavir should not be administered to treatment-naïve patients managed with haemodialysis.

Patients with hepatic impairment

Atazanavir Viatriis should be used with caution in patients with mild to moderate hepatic insufficiency. A dose reduction to 300 mg once daily should be considered for patients with moderate hepatic insufficiency (Child-Pugh Class B). Atazanavir Viatriis should not be used in patients with severe hepatic insufficiency (Child-Pugh Class C, see sections 4.3, 4.4 and 5.2). Atazanavir in combination with ritonavir has not been studied in subjects with hepatic impairment and should be used with caution in patients with mild hepatic impairment. Atazanavir Viatriis with ritonavir is not recommended for patients with moderate to severe impairment.

Dosing during pregnancy and the postpartum period

See section 4.6 for further information.

4.3 Contraindications

Hypersensitivity to atazanavir or to any of the excipients (see list of excipients in section 6.1).

Patients with severe hepatic insufficiency. Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2, 4.4 and 5.2).

Atazanavir Viatriis is contraindicated in combination with:

- rifampicin
- apalutamide
- lurasidone
- simvastatin or lovastatin
- lomitapide
- medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 and have narrow therapeutic windows. Co-administration may result in competitive inhibition of the metabolism of these medicinal products and create the potential for serious and/or life-threatening adverse events such as cardiac arrhythmia (e.g. cisapride, pimozide), prolonged sedation or respiratory depression (e.g. orally administered midazolam, triazolam), or other events (e.g. ergot derivatives)
- products containing St. John's wort (*Hypericum perforatum*)
- alfuzosin
- salmeterol
- elbasvir/grazoprevir
- glecaprevir/pibrentasvir
- sildenafil when used for the treatment of pulmonary arterial hypertension.

See section 4.5 for the list of medicines that are contraindicated or not recommended for co-administration with atazanavir.

4.4 Special warnings and precautions for use

Hyperbilirubinemia and jaundice

Most patients taking atazanavir experience asymptomatic elevations in indirect (unconjugated) bilirubin, and this may be associated with scleral icterus and jaundice in some patients. This isolated hyperbilirubinemia is reversible upon discontinuation of atazanavir. Hyperbilirubinemia was related to atazanavir plasma concentrations and not generally associated with elevation of serum transaminases. Preclinical studies suggest that elevation in bilirubin was not associated with haemolysis and was related to inhibition of UDP-glucuronosyl transferase (UGT) by atazanavir. Hepatic transaminase elevations that occur with hyperbilirubinemia should be evaluated for alternative etiologies. No long-term safety data are available for patients experiencing persistent elevations in total bilirubin > 5 times ULN. Alternative antiretroviral therapy to atazanavir may be considered if jaundice or scleral icterus associated with bilirubin elevations presents cosmetic

concerns for patients. Dose reduction of atazanavir is not recommended since long-term efficacy of reduced doses has not been established (see section 4.8).

Cardiac effects

Atazanavir has been shown to prolong the PR interval of the electrocardiogram in some patients. In healthy volunteers and in patients, abnormalities in atrioventricular (AV) conduction were asymptomatic and generally limited to first-degree AV block. There have been rare reports of second-degree AV block and other conduction abnormalities (see section 4.9). In clinical trials, asymptomatic first-degree AV block was observed in 5.9% of atazanavir-treated patients (n=920), 5.2% of lopinavir/ritonavir-treated patients (n=252), 10.4% of nelfinavir-treated patients (n=48), and in 3.0% of efavirenz-treated patients (n=329). There has been no second- or third-degree AV block.

In Study AI424-045, asymptomatic first-degree AV block was observed in 5% (6/118) of atazanavir/ritonavir-treated patients and 5% (6/116) of lopinavir/ritonavir-treated patients who had on-study electrocardiogram measurements.

Because of limited clinical experience, Atazanavir Viartis should be used with caution in patients with pre-existing conduction system disease (e.g. marked first-degree AV block or second- or third-degree AV block) (see section 5.1).

In a pharmacokinetic study between atazanavir 400 mg once daily and diltiazem 180 mg once daily, a CYP3A4 substrate, there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval. When used in combination with atazanavir, a dose reduction of diltiazem by one half should be considered and electrocardiographic monitoring is recommended. In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, there was no substantial additive effect of atazanavir and atenolol on the PR interval. When used in combination with atazanavir, there is no need to adjust the dose of atenolol (see section 4.5).

Pharmacokinetic studies between atazanavir and other medicines that prolong the PR interval including beta blockers (other than atenolol), calcium channel blockers (other than diltiazem), digoxin, and other antiarrhythmic medicines have not been performed. An additive effect of atazanavir and these medicines cannot be excluded; therefore, caution should be exercised when atazanavir is given concurrently with these medicines, especially those that are metabolized by CYP3A4 (e.g. calcium channel blockers). (See section 4.5). Particular caution should be used when prescribing Atazanavir Viartis in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances).

Rash

In controlled clinical trials (n=1597), rash (all grades, regardless of causality) occurred in 21% of patients treated with atazanavir. Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 3 weeks of initiating therapy with atazanavir. In most patients, rash resolves within 2 weeks while continuing atazanavir therapy. The discontinuation rate for rash in clinical trials was 0.4%. Atazanavir should be discontinued if severe rash develops.

Cases of Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions including medicine rash, eosinophilia and systemic symptoms (DRESS) syndrome have been reported in patients receiving atazanavir. Patients should be advised of the signs and symptoms and monitored closely for skin reactions.

Haemophilia

There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in type A and B haemophiliac patients treated with protease inhibitors. In some patients additional factor VIII was given. In most reported cases, treatment with protease inhibitors was continued or reintroduced if treatment had been discontinued. A causal relationship between

protease inhibitor therapy and these events has not been established. Haemophilic patients should therefore be made aware of the possibility of increased bleeding.

Fat redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

Diabetes/hyperglycaemia

New onset diabetes mellitus, hyperglycaemia, and exacerbation of existing diabetes mellitus have been reported during postmarketing surveillance in HIV-infected patients receiving protease inhibitors. In some of these, the hyperglycaemia was severe and in some cases also associated with ketoacidosis. Many patients had confounding medical conditions, some of which required therapy with agents that have been associated with development of diabetes or hyperglycaemia.

Immune reconstitution syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including atazanavir. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jiroveci* pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.

Lactic acidosis

Cases of lactic acidosis, sometimes fatal, and symptomatic hyperlactatemia have been reported in patients receiving atazanavir in combination with nucleoside analogues, which are known to be associated with increased risk of lactic acidosis. In studies where didanosine and stavudine were administered with atazanavir to patients without prior antiretroviral therapy, lactic acidosis/symptomatic hyperlactatemia was observed in 2.2% of subjects. Female gender and obesity are known risk factors for lactic acidosis. The contribution of atazanavir to the risk of development of lactic acidosis has not been established.

Rare lactose/galactose metabolic conditions

Patients with rare hereditary problems of galactose intolerance, glucose/galactose malabsorption or the Lapp lactase deficiency should not take Atazanavir Viatris.

Chronic kidney disease

Chronic kidney disease in HIV-infected patients treated with atazanavir, with or without ritonavir, has been reported during post-marketing surveillance. Atazanavir should be used with caution, particularly in those patients with other risk factors for chronic kidney disease.

Nephrolithiasis and cholelithiasis

Cases of nephrolithiasis and/or cholelithiasis have been reported during post-marketing surveillance in HIV-infected patients receiving atazanavir therapy. Some patients required hospitalisation for additional management and some had complications. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made. If signs or symptoms of nephrolithiasis and/or cholelithiasis occur, temporary interruption or discontinuation of therapy may be considered.

Impaired hepatic function

Atazanavir should be used with caution in patients with mild to moderate hepatic insufficiency. Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2, 4.4 and 5.2). Patients with underlying hepatitis B or C viral infections or marked elevations in transaminases prior to treatment may be at increased risk for developing further transaminase elevations or hepatic decompensation.

Use in elderly

No data available.

Use in children

Assessment of the pharmacokinetics, safety, tolerability, and efficacy of atazanavir is based on data from the open-label, multicenter clinical trial PACTG 1020A conducted in paediatric patients from 3 months to 21 years of age. In this study, 182 paediatric and adolescent patients (83 antiretroviral-naive and 99 antiretroviral-experienced) received once daily atazanavir, with or without ritonavir, in combination with two NRTIs. Atazanavir Viatrix is recommended for paediatric and adolescent patients from 6 years to 18 years of age (see section 4.2). There are no dosing recommendations for atazanavir in paediatric patients less than 6 years of age. Atazanavir Viatrix should not be administered to infants below the age of 3 months due to the risk of kernicterus.

Due to potential for inter-patient variability in atazanavir exposures, close monitoring of clinical status for efficacy (HIV RNA viral load and CD4 counts) and signs and symptoms of toxicity is recommended. In clinical trial PACTG 1020A, 50% of patients receiving the recommended capsule dosage regimen required an increase in atazanavir dose to maintain exposure within the target range based on therapeutic medicine monitoring. Therefore, consideration should also be given to using therapeutic medicine monitoring when it is available and well-validated.

Asymptomatic PR interval prolongation was more frequent in paediatric patients than in adults. Asymptomatic first-degree (23%) and second-degree (1%) AV block was observed in paediatric patients. Caution should be used with medicinal products known to induce PR prolongations. In paediatric patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), Atazanavir Viatrix should be used with caution and only if the benefits exceed the risk. Cardiac monitoring is recommended based on the presence of clinical findings (e.g. bradycardia).

Effects on Laboratory Tests

No data available.

4.5 Interaction with other medicines and other forms of interaction

Atazanavir is an inhibitor of CYP3A4 and UGT1A1. Co-administration of atazanavir and medicines primarily metabolized by CYP3A4 (e.g. calcium channel blockers, HMG-CoA reductase inhibitors, immunosuppressants, and phosphodiesterase inhibitors) or UGT1A1 (e.g. irinotecan) may result in increased plasma concentrations of the other medicine that could increase or prolong both its therapeutic and adverse effects (see Tables 14 and 15). Atazanavir is metabolized in the liver by the cytochrome P450 enzyme system. Co-administration of atazanavir and medicines that induce CYP3A4, such as rifampicin, may decrease atazanavir plasma concentrations and reduce its therapeutic effect. Co-administration of atazanavir and medicines that inhibit CYP3A4 may increase atazanavir plasma concentrations.

The magnitude of CYP3A4-mediated medicine interactions (effect on atazanavir or effect on co-administered medicine) may change when atazanavir is co-administered with ritonavir, a potent CYP3A4 inhibitor. The prescribing information for ritonavir should be consulted for information on medicine interactions with ritonavir.

Atazanavir solubility decreases as pH increases. The recommended oral dosage of atazanavir depends on the treatment history of the patient and the use of co-administered medicines. Reduced plasma concentrations of atazanavir may occur if antacids, proton-pump inhibitors, buffered medications, and H₂-receptor antagonists, are administered with atazanavir. Please refer to Table 3 and section 4.2 for recommendations for use of atazanavir with gastric acid lowering medications.

Atazanavir has the potential to prolong the PR interval of the electrocardiogram in some patients. Caution should be used when co-administering atazanavir with medicinal products known to induce PR interval prolongation (e.g. atenolol, diltiazem).

Medicines that are contraindicated or not recommended for co-administration with atazanavir are included in Table 2. These recommendations are based on either medicine interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.

Table 2 : Medicines That Should Not Be Administered with Atazanavir

Medicine class: Specific Medicines	Clinical Comment
Alpha 1-adrenoceptor antagonist: alfuzosin	CONTRAINDICATED Potential for increased alfuzosin concentration which can result in hypotension.
Antimycobacterials: rifampicin	CONTRAINDICATED Decreases plasma concentrations and AUC of most protease inhibitors by about 90%. This may result in loss of therapeutic effect and development of resistance.
Antipsychotics: lurasidone	CONTRAINDICATED Potential for serious and/or life-threatening reactions if atazanavir is co-administered with lurasidone
Antineoplastics: irinotecan	Atazanavir inhibits UGT and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities.
Apalutamide	CONTRAINDICATED Apalutamide is expected to substantially decrease plasma concentrations of atazanavir and ritonavir, which may result in loss of virologic response and possible resistance to atazanavir and/or ritonavir or other protease inhibitors.
Benzodiazepines: orally administered midazolam*, triazolam	CONTRAINDICATED due to potential for serious and/or life-threatening events such as prolonged or increased sedation or respiratory depression (see Table 3 for parenteral midazolam).
Calcium Channel Blockers: bepridil	Potential for serious and/or life-threatening adverse events.
Ergot Derivatives: dihydroergotamine, ergotamine, ergonovine, methylergonovine	CONTRAINDICATED due to potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
GI Motility Agent: cisapride	CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Hepatitis C Direct-Acting Antivirals: elbasvir/grazoprevir	CONTRAINDICATED because of the potential increase in the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition.
Glecaprevir/pibrentasvir	CONTRAINDICATED because of the increased risk of ALT elevations due to an increase in glecaprevir and pibrentasvir plasma concentrations.
HMG-CoA Reductase Inhibitors: lovastatin, simvastatin.	CONTRAINDICATED Potential for serious reactions such as myopathy including rhabdomyolysis. (See also Table 3).

Other Lipid-Modifying Agents: lomitapide	CONTRAINDICATED because of the potential for risk of markedly increased transaminase levels and hepatotoxicity associated with increased plasma concentrations of lomitapide. The mechanism of interaction is CYP3A4 by atazanavir and/or ritonavir.
Neuroleptic: pimozide	CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Protease Inhibitors: indinavir	Both atazanavir and indinavir are associated with indirect (unconjugated) hyperbilirubinemia. Combinations of these medicines have not been studied and co-administration of atazanavir and indinavir is not recommended.
PDE5 inhibitor: sildenafil** for the treatment of pulmonary arterial hypertension.	CONTRAINDICATED A safe and effective dose in combination with atazanavir has not been established for sildenafil when used for the treatment of pulmonary arterial hypertension. There is increased potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, priapism, and syncope).
Herbal Products: St. John's wort (<i>Hypericum perforatum</i>)	CONTRAINDICATED Patients taking atazanavir should not use products containing St. John's wort (<i>Hypericum perforatum</i>) because co-administration may be expected to reduce plasma concentrations of atazanavir. This may result in loss of therapeutic effect and development of resistance.
Inhaled beta agonists: salmeterol	CONTRAINDICATED Concomitant use of salmeterol and atazanavir may result in increased cardiovascular events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia. Co-administration of salmeterol and atazanavir is not recommended.

Table 2 b : Medicines That Should Not Be Administered when Atazanavir is administered with Ritonavir

The metabolic profile for ritonavir may predominate when used in combination with atazanavir because ritonavir is a more potent CYP3A4 inhibitor than atazanavir. The product information for ritonavir should be consulted when atazanavir is boosted with ritonavir.

Medicine class:	Clinical Comment
Specific Medicines	
Anti-arrhythmics: quinidine	Atazanavir/ritonavir: CONTRAINDICATED if atazanavir is co-administrated with ritonavir due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Calcium Channel Blockers: bepridil	Potential for serious and/or life-threatening adverse events. CONTRAINDICATED if atazanavir is co-administered with ritonavir.

* see Table 3, Other Agents: Benzodiazepines.

** see Table 3 for sildenafil dosing recommendations when used to treat erectile dysfunction.

In a clinical study of co-administration to healthy subjects of ritonavir 100 mg twice daily and intranasal fluticasone propionate 50 micrograms four times daily for 7 days, the fluticasone propionate plasma levels increased significantly whereas the intrinsic cortisol levels decreased by approximately 86% (90% CI 82%, 89%). The effect of high fluticasone systemic exposure on ritonavir plasma levels is not yet known.

Systemic corticosteroid effects have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate. Concomitant use of atazanavir/ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 (e.g. budesonide) is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effect (e.g. Cushing's syndrome and adrenal suppression). Use of a corticosteroid that is not metabolised by CYP3A4, (e.g. beclomethasone), could be considered.

In the case of withdrawal of fluticasone propionate co-administered with ritonavir, progressive dose reduction may have to be performed over a longer period.

Table 3: Established and Other Potentially Significant Medicine Interactions: Alteration in Dose or Regimen May Be Recommended Based on Medicine Interaction Studies or Predicted Interactions^a

Concomitant Medicine Class: Specific Medicines	Effect on Concentration of Atazanavir or Concomitant Medicine	Clinical Comment
<i>HIV Antiviral Agents</i>		
Nucleoside Reverse Transcriptase Inhibitors (NRTIs): didanosine buffered formulations	↓ atazanavir	Co-administration with atazanavir did not alter exposure to didanosine; however, exposure to atazanavir was markedly decreased by co-administration of atazanavir with didanosine buffered tablets (presumably due to the increase in gastric pH caused by buffers in the didanosine tablets). In addition, it is recommended that didanosine be administered on an empty stomach; therefore, atazanavir should be given (with food) 2 h before or 1 h after didanosine buffered formulations. Because didanosine EC capsules are to be given on an empty stomach and atazanavir is to be given with food, they also should be administered at different times.
Nucleotide Reverse Transcriptase Inhibitors: tenofovir disoproxil fumarate	↓ atazanavir	<p>Tenofovir may decrease the AUC and C_{min} of atazanavir. When co-administered with tenofovir, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg and tenofovir 300 mg (all as a single daily dose with food). Atazanavir without ritonavir should not be co-administered with tenofovir.</p> <p>Atazanavir increases tenofovir disoproxil fumarate concentrations. The mechanism of this interaction is unknown. Higher tenofovir disoproxil fumarate concentrations could potentiate tenofovir disoproxil fumarate-associated adverse events, including renal disorders. Patients receiving atazanavir and tenofovir disoproxil fumarate should be monitored for tenofovir disoproxil fumarate-associated adverse events.</p>
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs): efavirenz	↓ atazanavir	Efavirenz decreases atazanavir exposure. Co-administration of atazanavir and efavirenz is not recommended for treatment-experienced or treatment-naïve patients due to decreased atazanavir exposure. However, if judged unavoidable in treatment-naïve patients, dose recommendations are included in section 4.2.
Non-nucleoside Reverse Transcriptase Inhibitors: nevirapine	↓ atazanavir	Nevirapine substantially decreases atazanavir exposure. There is potential risk for nevirapine associated toxicity due to increased nevirapine exposures. Co-administration of atazanavir with nevirapine is not recommended.

Protease Inhibitors: saquinavir (soft gelatin capsules)	↑ saquinavir	Appropriate dosing recommendations for this combination, with respect to efficacy and safety, have not been established. A total daily dose of saquinavir of 1200 mg once daily co-administered with atazanavir 400 mg once daily has been explored in a clinical study but has not been shown to provide adequate efficacy (see section 5.1).
Protease Inhibitors: ritonavir	↑ atazanavir	If atazanavir is co-administered with ritonavir, it is recommended that atazanavir 300 mg once daily be given with ritonavir 100 mg once daily with food. See the complete prescribing information for ritonavir for information on medicine interactions with ritonavir.
Other protease inhibitors	↑ protease inhibitor	Although not studied, the co-administration of atazanavir plus ritonavir with other protease inhibitors would be expected to increase exposure to the other protease inhibitor and is not recommended.

HCV Antiviral Agents

Protease Inhibitors: boceprevir	↓ atazanavir	Exposure to atazanavir was decreased when boceprevir at 800 mg three times daily was co-administered with atazanavir 300 mg and ritonavir 100 mg once daily. Exposure to boceprevir was not significantly altered.
Protease inhibitors: voxilaprevir	↑ voxilaprevir	Co-administration of the fixed dose combination sofosbuvir/velpatasvir/voxilaprevir with atazanavir resulted in increased voxilaprevir plasma concentrations. Co-administration of voxilaprevir with atazanavir is not recommended.

Other Agents

Antacids and buffered medications	↓ atazanavir	Reduced plasma concentrations of atazanavir are expected if antacids, including buffered medications, are administered with atazanavir. Atazanavir should be administered 2 h before or 1 h after these medications.
Antiarrhythmics: amiodarone, lidocaine (systemic), quinidine	↑ amiodarone, lidocaine (systemic), quinidine	Co-administration with atazanavir has the potential to produce serious and/or life-threatening adverse events and has not been studied. Concentration monitoring of these medicines is recommended if they are used concomitantly with atazanavir. Quinidine is contraindicated when atazanavir is co-administered with ritonavir.
Anticoagulants: Vitamin K Antagonists: warfarin	↑ warfarin	Co-administration with atazanavir has the potential to produce serious and/or life-threatening bleeding and has not been studied. It is recommended that INR (International Normalized Ratio) be monitored.

Direct-acting oral anticoagulants (DOACs): betrixaban, dabigatran, edoxaban	↑ betrixaban, dabigatran, edoxaban	Concomitant use of atazanavir and RTV, a strong CYP3A4/P-gp inhibitor, with either betrixaban, dabigatran, or edoxaban may result in an increased exposure of the DOAC, which could lead to an increased risk of bleeding. Refer to the respective DOAC prescribing information regarding dosing instructions for co-administration with P-gp inhibitors.
Rivaroxaban	↑ rivaroxaban	Concomitant use of atazanavir and RTV, a strong CYP3A4/P-gp inhibitor, and rivaroxaban may result in increased exposure of rivaroxaban, which could lead to an increased risk of bleeding. Avoid concomitant use of atazanavir and RTV with rivaroxaban. Concomitant use of atazanavir, a CYP3A4 inhibitor, and rivaroxaban, may result in increased exposure of rivaroxaban, which could lead to an increased risk of bleeding. Close monitoring is recommended when rivaroxaban is co-administered with atazanavir.
Apixaban	↑ apixaban	Concomitant use of atazanavir and RTV, a strong CYP3A4/P-gp inhibitor, with apixaban may result in increased exposure of apixaban, which could lead to an increased risk of bleeding. Refer to apixaban dosing instructions for co-administration with strong CYP3A4 and P-gp inhibitors in apixaban prescribing information. Concomitant use of atazanavir, a CYP3A4 inhibitor, and apixaban may result in increased exposure of apixaban, which could lead to an increased risk of bleeding. Close monitoring is recommended when apixaban is co-administered with atazanavir.
Antiplatelets: ticagrelor	↑ ticagrelor	Co-administration with ticagrelor is not recommended due to potential increase in the antiplatelet activity of ticagrelor.
clopidogrel	↓ clopidogrel	Co-administration with clopidogrel is not recommended due to potential reduction of the antiplatelet activity of clopidogrel.
prasugrel	↔ prasugrel active metabolite	No dose adjustment is needed when prasugrel is co-administered with atazanavir with or without ritonavir.
Antineoplastics: apalutamide	↓ atazanavir	Co-administration with atazanavir with or without ritonavir is contraindicated due to the potential for decreased atazanavir and ritonavir plasma concentration with subsequent loss of virologic response and possible resistance to the class of protease inhibitors.
encorafenib	↑ encorafenib	Avoid co-administration of encorafenib with atazanavir with or without ritonavir due to potential for increase in encorafenib plasma concentration and subsequent risk of serious adverse events such as QT interval prolongation. If co-administration of encorafenib with atazanavir with or without ritonavir cannot be avoided, modify encorafenib dose as recommended for co-administration with strong and moderate CYP3A4 inhibitors in the local prescribing information.

ivosidenib	↑ ivosidenib	Avoid co-administration of ivosidenib with atazanavir with or without ritonavir due to potential for increase in ivosidenib plasma concentration and subsequent risk of serious adverse events such as QT interval prolongation. If co-administration of ivosidenib with atazanavir with or without ritonavir cannot be avoided, modify ivosidenib dose as recommended for co-administration with strong and moderate CYP3A4 inhibitors in the local prescribing information.
Antidepressants: tricyclic antidepressants	↑ tricyclic antidepressants	Co-administration with atazanavir has the potential to produce serious and/or life-threatening adverse events and has not been studied. Concentration monitoring of these medicines is recommended if they are used concomitantly with atazanavir.
Trazodone	↑ trazodone	Concomitant use of trazodone and atazanavir with or without ritonavir may increase plasma concentrations of trazodone. Adverse event of nausea, dizziness, hypotension and syncope have been observed following co-administration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as atazanavir, the combination should be used with caution and a lower dose of trazodone should be considered.
Antiepileptics: Carbamazepine	↓ atazanavir	Plasma concentrations of atazanavir may be decreased when carbamazepine is administered with atazanavir without ritonavir. Co-administration of carbamazepine and atazanavir without ritonavir is not recommended. Ritonavir may increase plasma levels of carbamazepine. If patients beginning treatment with atazanavir/ritonavir have been titrated to a stable dose of carbamazepine, a dose reduction for carbamazepine may be necessary.
Phenytoin, phenobarbital	↓ atazanavir	Plasma concentrations of atazanavir may be decreased when phenytoin or phenobarbital is administered with atazanavir without ritonavir. Co-administration of phenytoin or phenobarbital and atazanavir without ritonavir is not recommended. Ritonavir may decrease plasma levels of phenytoin and phenobarbital. When atazanavir with ritonavir is co-administered with either phenytoin or phenobarbital, a dose adjustment of phenytoin or phenobarbital may be required.
Lamotrigine	↓ lamotrigine:	Co-administration of lamotrigine and atazanavir with ritonavir may decrease lamotrigine plasma concentrations. Dose adjustment of lamotrigine may be required when co-administered with atazanavir and ritonavir. Co-administration of lamotrigine and atazanavir without ritonavir is not expected to decrease lamotrigine plasma concentrations. No dose adjustment of lamotrigine is required when co-administered with atazanavir without ritonavir

Antifungals: ketoconazole, itraconazole	↑ atazanavir ↑ ritonavir	Co-administration of ketoconazole has only been studied with atazanavir without ritonavir (negligible increase in atazanavir AUC and C _{max}). Plasma levels of both atazanavir and ritonavir may be increased by ketoconazole and itraconazole. High doses of ketoconazole and itraconazole (>200 mg/day) should be used cautiously with atazanavir and ritonavir.
Antifungal: voriconazole	↓ atazanavir ↓ voriconazole (with at least one functional CYP2C19 allele) ↑ voriconazole (without a functional CYP2C19 allele)	Co-administration of voriconazole (200 mg twice daily) with atazanavir/ritonavir (300/100 mg once daily) in subjects with at least one functional CYP2C19 allele decreased plasma concentrations of both voriconazole and atazanavir. Co-administration of voriconazole (50 mg twice daily) with atazanavir/ritonavir (300/100 mg once daily) in subjects without a functional CYP2C19 allele increased plasma concentrations of voriconazole and decreased plasma concentrations of atazanavir. Voriconazole should not be administered to patients receiving atazanavir and ritonavir unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. Patients should be carefully monitored for voriconazole-associated adverse events and loss of either voriconazole or atazanavir efficacy during the co-administration of voriconazole and atazanavir/ritonavir.
Antimycobacterials: rifabutin	↑ rifabutin	Exposure to rifabutin is increased when it is co-administered with atazanavir. A rifabutin dose reduction of up to 75% (e.g. 150 mg every other day or 3 times per week) is recommended. Increased monitoring for adverse reactions is warranted in patients receiving the combination of rifabutin and atazanavir with or without ritonavir. Further dosage reduction of rifabutin may be necessary.
Antipsychotics: lurasidone	↑ lurasidone	The use of lurasidone with atazanavir boosted with ritonavir is contraindicated. If co-administration of lurasidone with atazanavir without ritonavir is necessary, reduce the lurasidone dose. Refer to the lurasidone prescribing information for concomitant use with moderate CYP3A4 inhibitors.
Calcium channel blockers: diltiazem	↑ diltiazem and desacetyl-diltiazem	Caution is warranted. A dose reduction of diltiazem by 50% should be considered. ECG monitoring is recommended.
e.g. felodipine, nifedipine, nicardipine, and verapamil	↑ calcium channel blocker	Caution is warranted. Dose titration of the calcium channel blocker should be considered. ECG monitoring is recommended.
Gonadotropin-releasing hormone antagonist Receptor (GnRH) Antagonists: elagolix	↑ elagolix	Concomitant use of elagolix 200 mg twice daily with atazanavir with or without ritonavir for more than 1 month is not recommended due to the potential risk of adverse events such as bone

H₂-Receptor antagonists;
famotidine.

↓ atazanavir

Reduced plasma concentrations of atazanavir are expected if H₂-receptor antagonists are administered with atazanavir. This may result in loss of therapeutic effect and development of resistance.

In treatment-naïve patients:

The H₂-receptor antagonist dose should not exceed a 40 mg dose equivalent of famotidine twice daily. Atazanavir 300 mg with ritonavir 100 mg once daily (all as a single dose with food) should be administered simultaneously with, and/or at least 10 hours after, the dose of the H₂-receptor antagonist.

In treatment-experienced patients:

Whenever a H₂-receptor antagonist is given to a patient receiving atazanavir with ritonavir, the H₂-receptor antagonist dose should not exceed a dose equivalent to famotidine 20 mg twice daily, and the atazanavir and ritonavir doses should be administered simultaneously with, and/or at least 10 hours after, the dose of the H₂-receptor antagonist.

- Atazanavir 300 mg with ritonavir 100 mg once daily (all as a single dose with food) if taken with a H₂-receptor antagonist and without tenofovir.
- Atazanavir 400 mg with ritonavir 100 mg once daily (all as a single dose with food) if taken with both tenofovir and a H₂-receptor antagonist.

Immunosuppressants:
cyclosporin,
sirolimus,
tacrolimus

↑ immuno-
suppressants

Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with atazanavir.

Dexamethasone and other
corticosteroids (all routes of
administration)

↓ atazanavir

Co-administration with dexamethasone or other corticosteroids that induce CYP3A may result in loss of therapeutic effect of atazanavir and development of resistance to atazanavir and/or ritonavir. Alternative corticosteroids should be considered. Co-administration with corticosteroids (all routes of administration) that are metabolised by CYP3A4, particularly for long-term use, may increase the risk for development of systemic corticosteroid effects including Cushing's syndrome and adrenal suppression. Consider the potential benefit of treatment versus the risk of systemic corticosteroid effects.

For co-administration of cutaneously-administered corticosteroids sensitive to CYP3A inhibition, refer to the prescribing information of the corticosteroid for conditions or uses which augment its systemic absorption. The mechanism of interaction is CYP3A4 induction by dexamethasone and CYP3A4 inhibition by atazanavir and/or ritonavir.

Macrolide antibiotics: clarithromycin	↑ clarithromycin ↓ 14-OH clarithromycin ↑ atazanavir	Increased concentrations of clarithromycin may cause QTc prolongations; therefore, a dose reduction of clarithromycin by 50% should be considered when it is co-administered with atazanavir. In addition, concentrations of the active metabolite 14-OH clarithromycin are significantly reduced; consider alternative therapy for indications other than infections due to <i>Mycobacterium avium</i> complex.
Benzodiazepines: Parenteral midazolam	↑ benzodiazepine	Midazolam is extensively metabolized by CYP3A4. Although not studied, co-administration of midazolam with atazanavir may cause a large increase in the concentration of this benzodiazepine. Increases in benzodiazepine concentration are expected to be significantly higher with oral administration of the benzodiazepine, relative to parenteral administration. Therefore, atazanavir should not be co-administered with orally administered midazolam, whereas caution should be used with co-administration of atazanavir and parenteral midazolam. No data are available on concomitant use of atazanavir with intravenous midazolam; data from concomitant use of other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels. If atazanavir is co-administered with parenteral midazolam, close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised and dosage adjustments should be assessed.
Oral contraceptives: ethinyl estradiol and norgestimate or norethindrone	↓ ethinyl estradiol ↑ norgestimate (In combination with atazanavir 300 mg and ritonavir 100 mg once daily).	Mean concentrations of ethinyl estradiol and norethindrone are increased when they are co-administered with atazanavir. Administration of atazanavir/ritonavir with ethinyl estradiol and norgestimate decreases the mean concentration of ethinyl estradiol, and increases the mean concentration of 17-deacetylnorgestimate, the active metabolite of norgestimate.
	↑ ethinyl estradiol ↑ norethindrone (In combination with atazanavir 400 mg once daily.)	Co-administration of atazanavir or atazanavir/ritonavir with other hormonal contraceptives (e.g. contraceptive patch, contraceptive vaginal ring, or injectable contraceptives) or oral contraceptives containing progestagens other than norethindrone or norgestimate, or less than 25 µg of ethinyl estradiol have not been studied; therefore alternative methods of contraception are recommended.

Proton Pump Inhibitors: omeprazole	↓ atazanavir	<p>Plasma concentrations of atazanavir were substantially decreased when atazanavir 400 mg or atazanavir 300 mg/ritonavir 100 mg once daily was administered with omeprazole 40 mg once daily, which may result in loss of therapeutic effect and development of resistance.</p> <p><i>In treatment-naïve patients:</i> The proton-pump inhibitor dose should not exceed a 20 mg dose equivalent of omeprazole and must be taken approximately 12 hours prior to the atazanavir 300 mg with ritonavir 100 mg dose. Atazanavir without ritonavir should not be co-administered with omeprazole.</p> <p><i>In treatment-experienced patients:</i> Proton-pump inhibitors should not be used in treatment-experienced patients receiving atazanavir.</p>
Opioid: Buprenorphine	↑ buprenorphine and norbuprenorphine	<p>Concentrations of buprenorphine and norbuprenorphine were increased when buprenorphine was co-administered with atazanavir, with or without ritonavir, due to CYP3A4 and UGT1A1 inhibition. Co-administration of atazanavir plus ritonavir with buprenorphine warrants clinical monitoring for sedation and cognitive effects. A dose reduction of buprenorphine may be considered. There was no significant effect of atazanavir plasma concentration when atazanavir plus ritonavir were co-administered with buprenorphine. Co-administration of buprenorphine and atazanavir without ritonavir may substantially decrease atazanavir plasma concentrations. Atazanavir without ritonavir should not be co-administered with buprenorphine.</p>
colchicine	↑ colchicine	<p>Exposure to colchicine may be increased when co-administered with atazanavir. Colchicine is a CYP3A4 substrate (see section 4.3 on the use of atazanavir with medications that are substrates for CYP3A4).</p>
Endothelin receptor antagonist: bosentan	↓ atazanavir	<p>Bosentan is metabolized by CYP3A4 and is an inducer of CYP3A4. Plasma concentrations of atazanavir may be decreased when bosentan is administered with atazanavir without ritonavir. Co-administration of bosentan and atazanavir without ritonavir is not recommended.</p> <p>Prescribers should consult the complete prescribing information for bosentan when considering using this medicine in combination with atazanavir and ritonavir.</p>

^a For magnitude of interactions see Tables 20 and 21.

Based on known metabolic profiles, clinically significant medicine interactions are not expected between atazanavir and fluvastatin, pravastatin, dapson, trimethoprim/sulfamethoxazole, azithromycin, erythromycin, itraconazole. There were no clinically significant medicine interactions

observed when atazanavir was co-administered with fluconazole or paracetamol. Atazanavir does not interact with substrates of CYP2D6 (e.g. nortriptyline, desipramine, metoprolol).

4.6 Fertility, pregnancy and lactation

Pregnancy

Fetal-Risk summary

No teratogenic effects were observed in rabbits exposed to a comparable human dose of 400 mg daily. No teratogenic effects were observed in rats exposed to the human equivalent of 800 mg daily. In the pre- and postnatal development assessment of rats, transient weight loss or suppression of weight gain occurred in the offspring at maternally toxic doses. Offspring were unaffected at a lower dose which produced maternal exposure equivalent to that observed in humans given 400 mg twice daily.

Clinical considerations

Atazanavir Viartis should be given during pregnancy only after special consideration of the potential benefits and risks (see section 4.4).

Atazanavir 300 mg with ritonavir 100 mg may not provide sufficient exposure to atazanavir, especially when the activity of atazanavir or the whole regimen may be compromised due to medicine resistance. Since there are limited data available and due to inter-patient variability during pregnancy, Therapeutic Drug Monitoring (TDM) may be considered to ensure adequate exposure.

This risk of further decrease in atazanavir exposure is expected when atazanavir is given with medicinal products known to reduce its exposure (e.g. tenofovir or H₂-receptor antagonists). If tenofovir or an H₂-receptor antagonist is needed, for treatment-experienced pregnant women during the second or third trimester, atazanavir 400 mg with ritonavir 100 mg once daily is recommended. There are insufficient data to recommend an atazanavir dose for use with *both* an H₂-receptor antagonist *and* tenofovir in treatment-experienced women. No dose adjustment is required for postpartum patients. Patients, however, should be closely monitored for adverse events because atazanavir exposures could be higher during the first two months after delivery.

In clinical trials, fatal cases of lactic acidosis have occurred in pregnant women receiving atazanavir in combination with nucleoside analogues, which are known to be associated with increased risk of lactic acidosis.

Hyperbilirubinaemia (predominantly unconjugated) occurred frequently during treatment with atazanavir. It is not known whether atazanavir administered to the mother during pregnancy will exacerbate physiological hyperbilirubinemia and lead to kernicterus in neonates and young infants. In the prepartum period, additional monitoring and alternative therapy to atazanavir should be considered.

Human data

Clinical Trials: In clinical trial AI424-182, atazanavir/ritonavir (300 mg/100 mg or 400 mg/100 mg) in combination with zidovudine/lamivudine was administered to 41 pregnant women during the second or third trimester. Among the 39 women who completed the study, 38 women achieved a HIV RNA <50 copies/mL at time of delivery. Six of 20 (30%) women on atazanavir/ritonavir 300 mg/100 mg and 13 of 21 (62%) women on atazanavir/ritonavir 400 mg/100 mg experienced Grades 3 to 4 hyperbilirubinemia. There were no cases of lactic acidosis observed in the clinical trial AI424-182.

Forty infants had test results that were negative for HIV-1 DNA at the time of delivery and/or during the first 6 months postpartum. All 40 infants received antiretroviral prophylactic treatment containing zidovudine. Three of 20 infants (15%) born to women treated with atazanavir/ritonavir 300 mg/100 mg and four of 20 infants (20%) born to women treated with atazanavir/ritonavir 400 mg/100 mg experienced Grade 3-4 bilirubin. There was no evidence of pathologic jaundice and six of 40 infants

in this study received phototherapy for a maximum of 4 days. There were no reported cases of kernicterus in neonates.

Post-Marketing data

As of December 2009, there were 315 identified cases with prospective first trimester exposure to atazanavir and known outcome in the post-marketing database. There was no association between atazanavir and specific birth defects observed in the post-marketing data.

Antiretroviral pregnancy registry data

As of January 2010, the Antiretroviral Pregnancy Registry (APR) has received prospective reports of 635 exposures to atazanavir-containing regimens (425 exposed in the first trimester and 160 and 50 exposed in second and third trimester, respectively). Birth defects occurred in 9 of 393 (2.3%) live births (first trimester exposure) and 5 of 212 (2.4%) live births (second/third trimester exposure). There was no association between atazanavir and specific birth defects observed in the APR.

Dosing during pregnancy and the postpartum period

- Atazanavir Viartis should not be administered without ritonavir (see also section 5.1);
- For pregnant patients, no dose adjustment is required for Atazanavir Viartis with the following exceptions:
 - For treatment-experienced pregnant women during the second or third trimester, when atazanavir is co-administered with either H₂-receptor antagonist or tenofovir, atazanavir 400 mg with ritonavir 100 mg once daily is recommended. There are insufficient data to recommend an atazanavir dose for use with both an H₂-receptor antagonist and tenofovir in treatment-experienced women.
 - No dose adjustment is required for postpartum patients. Patients, however, should be closely monitored for adverse events because atazanavir exposures could be higher during the first two months after delivery.

Breastfeeding

Atazanavir has been detected in human milk. No data are available regarding atazanavir effects on milk production.

Studies in rats revealed that atazanavir and/or its metabolites are excreted in the milk. Transient reductions in offspring body weights were observed in a pre- and post-natal development study in rats, at a dose that resulted in a systemic medicine exposure (AUC) that was approximately 2-fold higher than that expected in humans given the recommended dose.

Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to be breastfeed if they are receiving Atazanavir Viartis.

Fertility

Atazanavir produce no effects on mating, fertility or early embryonic development in rats at doses that provided exposures equivalent to (males) and at least two times (females) exposure in humans given 400 mg once daily. Altered oestrus cycles were observed in female rats treated with oral doses resulting in similar estimated systemic drug exposures (AUC).

4.7 Effects on ability to drive and use machines

Patients should be informed that dizziness has been reported during treatment with regimens containing atazanavir (see section 4.8).

4.8 Undesirable effects

Treatment-emergent adverse events in treatment-naive patients

Selected clinical adverse events of moderate or severe intensity reported in treatment-naïve patients receiving combination therapy including atazanavir 300 mg with ritonavir 100 mg or atazanavir 400 mg (without ritonavir) are presented in Table 4 and 5 respectively. For other information regarding observed or potentially serious adverse events, see section 4.4.

Table 4: Selected^a Treatment-Emergent Adverse Reactions^b of Moderate or Severe Intensity Reported in $\geq 2\%$ of Adult Treatment-naïve Patients^c, Study AI424-138 Phase III Study AI424-138

	96 weeks^d atazanavir 300 mg plus ritonavir 100 mg (once daily) and tenofovir plus emtricitabine^e (n=441)	96 weeks^d lopinavir 400 mg plus ritonavir 100 mg (twice daily) and tenofovir plus emtricitabine^e (n=437)
Digestive System		
Nausea	4%	8%
Jaundice/scleral icterus	5%	*
Diarrhoea	2%	12%
Skin and Appendages		
Rash	3%	2%

* None reported in this treatment arm.

^a Only clinical adverse reactions that were not laboratory abnormalities are included in the tablet. Laboratory abnormalities as measured on study are shown in Table 4

^b Includes events of possible, probable, certain, or unknown relationship to treatment regimen

^c Based on the regimen containing atazanavir

^d Median time on therapy

^e As a fixed-dose combination: 300 mg tenofovir, 200 mg emtricitabine once daily

Table 5: Selected Treatment-Emergent Adverse Events of Moderate or Severe Intensity Reported in $\geq 3\%$ of Adult Treatment-Naive Patients^a

	Phase III Study AI424-034		Phase II Studies AI424-007, -008	
	64 weeks ^b atazanavir 400 mg once daily + lamivudine + zidovudine ^d (n=404)	64 weeks ^b efavirenz 600 mg once daily + lamivudine + zidovudine ^d (n=401)	120 weeks ^{b,c} atazanavir 400 mg once daily + stavudine + lamivudine or + stavudine + didanosine (n=279)	73 weeks ^{b,c} nelfinavir 750 mg TID or 1250 mg BID + stavudine + lamivudine or + stavudine + didanosine (n=191)
Body as a Whole				
Headache	14%	13%	10%	8%
Fever	4%	6%	5%	5%
Pain	3%	2%	1%	2%
Fatigue	2%	2%	3%	2%
Back pain	2%	5%	6%	3%
Digestive System				
Nausea	16%	13%	10%	6%
Jaundice/ scleral icterus	7%	<1%	8%	*
Abdominal pain	6%	5%	10%	8%
Vomiting	6%	8%	8%	7%
Diarrhoea	6%	7%	8%	25%
Metabolic and Nutritional System				
Lipodystrophy	1%	1%	8%	3%
Musculoskeletal System				
Arthralgia	<1%	2%	4%	4%
Nervous System				
Depression	4%	5%	8%	3%
Insomnia	3%	5%	1%	<1%
Dizziness	3%	8%	1%	*
Peripheral neurologic symptoms	1%	2%	8%	7%
Respiratory System				
Increased cough	3%	4%	5%	1%
Skin and Appendages				
Rash	9%	13%	10%	3%

* None reported in this treatment arm.

^a Based on regimen(s) containing atazanavir.

^b Median time on therapy.

^c Includes long-term follow-up.

^d As a fixed-dose combination: 150 mg lamivudine, 300 mg zidovudine twice daily.

Treatment-emergent adverse events in treatment-experienced patients

In Phase III clinical trials, atazanavir has been studied in 144 treatment-experienced patients in combination with two NRTIs (Study 043) and in 229 treatment-experienced patients in combination with either ritonavir, tenofovir, and one NRTI or saquinavir, tenofovir, and one NRTI (Study 045).

Treatment-emergent adverse events in all atazanavir-treated patients

Atazanavir has been evaluated for safety and tolerability in combination therapy with other antiretroviral medicinal products in controlled clinical trials. There were 1151 patients with 52 weeks median duration of treatment who received atazanavir 400 mg once daily. There were 655 patients with 96 weeks median duration of treatment who received atazanavir 300 mg with ritonavir 100 mg. Adverse events were consistent between patients who received atazanavir 400 mg once daily and patients who received atazanavir 300 mg with ritonavir 100 mg once daily, except that jaundice and elevated total bilirubin levels were reported more frequently with atazanavir plus ritonavir.

Among patients who received atazanavir 400 mg once daily or atazanavir 300 mg with ritonavir 100 mg once daily, the only adverse events of any severity reported very commonly with at least a possible relationship to regimens containing atazanavir and one or more NRTIs were nausea (20%), diarrhoea (10%), and jaundice (13%). Among patients receiving atazanavir 300 mg with ritonavir 100 mg, the frequency of jaundice was 19%. In the majority of cases, jaundice was reported with a few days to a few months after the initiation of treatment (see section 4.4).

Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients, including loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy, and dorsocervical fat accumulation (buffalo hump).

Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia, and hyperlactataemia (see section 4.4).

Adult patients

The following adverse events of moderate intensity or greater with at least a possible relationship to regimens containing atazanavir and one or more NRTIs have also been reported. The frequency of adverse reactions listed below is defined using the following convention: very common ($\geq 1/10$), common ($\geq 1/100$, $<1/10$), uncommon ($\geq 1/1,000$, $<1/100$), rare ($\geq 1/10,000$, $<1/1,000$), or very rare ($<1/10,000$).

<i>Immune system disorder:</i>	uncommon: hypersensitivity
<i>Metabolism and nutrition disorders:</i>	uncommon: anorexia, appetite increased, weight decreased, weight gain
<i>Psychiatric disorders:</i>	uncommon: anxiety, insomnia, depression, disorientation, sleep disorder, abnormal dream
<i>Nervous system disorders:</i>	common: headache; uncommon: peripheral neuropathy, amnesia, dizziness, somnolence, dysgeusia;
<i>Eye disorders:</i>	common: scleral icterus
<i>Cardiac disorders and vascular disorders:</i>	uncommon: syncope, hypertension; rare: oedema, palpitation
<i>Respiratory, thoracic and mediastinal disorders:</i>	uncommon: dyspnea
<i>Gastrointestinal disorders:</i>	common: abdominal pain, diarrhoea, dyspepsia, nausea, vomiting; uncommon: flatulence, dry mouth, gastritis, pancreatitis, abdominal distension, stomatitis aphthous
<i>Hepatobiliary disorders:</i>	common: jaundice; uncommon: hepatitis; rare: hepatosplenomegaly
<i>Skin and subcutaneous tissue disorders:</i>	common: rash; uncommon: alopecia, pruritus, urticaria;

rare: eczema, vasodilatation, vesiculobullous rash

Musculoskeletal and connective tissue disorders: uncommon: arthralgia, muscle atrophy, myalgia;

rare: myopathy

Renal and urinary disorders:

uncommon: hematuria, nephrolithiasis, frequency of micturition, proteinuria;

rare: kidney pain

Reproductive system and breast disorders: uncommon: gynecomastia

General disorders and administration site conditions: common: asthenia, lipodystrophy syndrome, fatigue;

uncommon: chest pain, fever, malaise, gait disturbances

In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.

Paediatric and adolescent patients

Assessment of the pharmacokinetics, safety, tolerability and efficacy of atazanavir is based on data from the open-label, multicentre clinical trial PACTG 1020A conducted in paediatric patients from 3 months to 21 years of age. The safety profile of atazanavir in paediatric patients (6 to <18 years of age) is presented below.

The most common Grade 2-4 adverse events $\geq 5\%$, (regardless of causality) reported in paediatric patients were cough (21%), fever (18%), jaundice/scleral icterus (15%), rash (14%), vomiting (12%), diarrhoea (9%), headache (8%), peripheral oedema (7%), extremity pain (6%), nasal congestion (6%), oropharyngeal pain (6%), wheezing (6%) and rhinorrhoea (6%). Asymptomatic grade 2-4 atrioventricular block was reported in <2% of patients.

The most common Grade 3-4 laboratory abnormalities occurring in paediatric patients were elevation of total bilirubin ($\geq 54.72\mu\text{mol/L}$, 58%), neutropenia (9%) and hypoglycaemia (4%). All other Grade 3-4 laboratory abnormalities occurred with a frequency of less than 3%.

Post-marketing experience

The following events have been identified during post-approval use of atazanavir. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to their seriousness, frequency of reporting, or causal connection to atazanavir, or a combination of these factors.

Metabolism and nutrition disorders: hyperglycemia, diabetes mellitus

Renal and urinary disorders: nephrolithiasis, interstitial nephritis, chronic kidney disease

Hepatobiliary disorders: cholelithiasis, cholecystitis, cholestasis

Skin and subcutaneous tissue disorders: angioedema

Cardiac disorders and vascular disorders: second degree AV block, third-degree AV block, QTc prolongation, Torsades de pointes

Laboratory Abnormalities

The percentages of adult treatment-naïve patients treated with combination therapy including atazanavir 300 mg with ritonavir 100 mg and atazanavir 400 mg (without ritonavir) with Grade 3-4 laboratory abnormalities are presented in Table 6 and 7, respectively.

Table 6: Grade 3-4 Laboratory Abnormalities Reported in \geq 2% of Adult Treatment-Naïve Patients^a, Study AI424-138

Variable	Limit ^c	Phase III Study AI424-138	
		96 weeks ^b atazanavir 300 mg plus ritonavir 100 mg (once daily) and tenofovir plus emtricitabine ^d (n=441)	96 weeks ^b lopinavir 400 mg plus ritonavir 100 mg (twice daily) and tenofovir plus emtricitabine ^d (n=437)
Chemistry	High		
SGOT/AST	$\geq 5.1 \times \text{ULN}$	3%	1%
SGPT/ALT	$\geq 5.1 \times \text{ULN}$	3%	2%
Total Bilirubin	$\geq 2.6 \times \text{ULN}$	44%	<1%
Lipase	$\geq 2.1 \times \text{ULN}$	2%	2%
Creatine Kinase	$\geq 5.1 \times \text{ULN}$	8%	7%
Total Cholesterol	$\geq 240 \text{ mg/dL}$ (6.216 mmol/L)	11%	25%
Haematology	Low		
Neutrophils	< 750 cells/mm ³	5%	2%

a Based on the regimen containing atazanavir

b Median time on therapy

c ULN = upper limit of normal

d As a fixed-dose combination: 300 mg tenofovir, 200 mg emtricitabine once daily.

Table 7: Selected Grade 3-4 Laboratory Abnormalities Reported in \geq 2% of Adult Treatment-Naïve Patients^a, Studies AI424-034, AI424-007, and AI424-008

Variable	Limit ^d	Phase III Study AI424-034		Phase II Studies AI424-007, -008	
		64 weeks ^b atazanavir 400 mg once daily + lamivudine + zidovudine ^e (n=404)	64 weeks ^b efavirenz 600 mg once daily + lamivudine + zidovudine ^e (n=401)	120 weeks ^{b,c} atazanavir 400 mg once daily + stavudine + lamivudine or + stavudine + didanosine (n=279)	73 weeks ^{b,c} nelfinavir 750 mg TID or 1250 mg BID + stavudine + lamivudine or + stavudine + didanosine (n=191)
Chemistry	High				
SGOT/AST	$\geq 5.1 \times \text{ULN}$	2%	2%	7%	5%
SGPT/ALT	$\geq 5.1 \times \text{ULN}$	4%	3%	9%	7%
Total Bilirubin	$\geq 2.6 \times \text{ULN}$	35%	<1%	47%	3%
Amylase	$\geq 2.1 \times \text{ULN}$	*	*	14%	10%
Lipase	$\geq 2.1 \times \text{ULN}$	<1%	1%	4%	5%
Hematology	Low				
Hemoglobin	<8.0 g/dL	5%	3%	<1%	4%
Neutrophils	<750 cells/mm ³	7%	9%	3%	7%

* None reported in this treatment arm. Amylase was not routinely tested in the protocol.

a Based on regimen(s) containing atazanavir.

b Median time on therapy.

c Includes long-term follow-up.

d ULN=upper limit of normal, grading system used is the Modified WHO system for grading acute and subacute toxicity effects.

e As a fixed-dose combination: 150 mg lamivudine, 300 mg zidovudine twice daily.

The percentages of adult treatment-experienced patients treated with combination therapy including atazanavir with Grade 3-4 laboratory abnormalities are presented in Table 8.

Table 8: Selected Grade 3-4 Laboratory Abnormalities Reported in \geq 2% of Adult Treatment-Experienced Patients^a

Variable	Limit ^d	Phase III Study AI424-043	Phase III Study AI424-045	Phase III Study AI424-045	Phase III Study AI424-045
		48 weeks ^b atazanavir 400 mg once daily + 2 NRTIs (n=144)	48 weeks ^c lopinavir + ritonavir (400/100 mg) BID ^e + 2 NRTIs (n=146)	96 weeks ^b atazanavir 300 mg once daily + ritonavir 100 mg once daily + tenofovir + NRTI (n=119)	96 weeks ^c lopinavir + ritonavir (400/100 mg) BID ^e + tenofovir + NRTI (n=118)
Chemistry	High				
SGOT/AST	$\geq 5.1 \times$ ULN	3%	3%	3%	4%
SGPT/ALT	$\geq 5.1 \times$ ULN	7%	3%	5%	3%
Total Bilirubin	$\geq 2.6 \times$ ULN	25%	<1%	53%	<1%
Lipase	$\geq 2.1 \times$ ULN	4%	3%	11%	13%
Hematology	Low				
Platelets	<50,000 /mm ³	0	0	5%	5%
Neutrophils	<750 cells/mm ³	6%	5%	8%	10%

a Based on regimen(s) containing atazanavir.

b Study 043 Median time on therapy.

c Median time on therapy for study 045 was 76 weeks.

d ULN=upper limit of normal.

e As a fixed-dose combination.

The most frequently reported laboratory abnormality in patients receiving regimens containing atazanavir and one or more NRTIs was elevated total bilirubin reported predominantly as elevated indirect [unconjugated] bilirubin (87% Grade 1, 2, 3, or 4). Grade 3 or 4 elevation of total bilirubin was noted 37% (6% Grade 4). Among experienced patients treated with atazanavir 300 mg once daily with 100 mg ritonavir once daily for a median duration of 95 weeks, 53% had Grade 3-4 total bilirubin elevations. Among naïve patients treated with atazanavir 300 mg once daily with 100 mg ritonavir once daily for a median duration of 96 weeks, 48% had Grade 3-4 total bilirubin elevations.

Other marked clinical laboratory abnormalities (Grade 3 or 4) reported in \geq 2% of patients receiving regimens containing atazanavir and or more NRTIs included: elevated creatine kinase (7%), elevated alanine aminotransferase/serum glutamic-pyruvic transaminase (ALT/SGPT) (5%), low neutrophils (5%), elevated aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) (3%), and elevated lipase (3%)

Two percent of patients treated with atazanavir experienced concurrent Grade 3-4 ALT/AST and Grade 3-4 total bilirubin elevations.

Other special populations

Patients co-infected with hepatitis B and/or hepatitis C virus

Liver function tests should be monitored in patients with a history of hepatitis B or C.

Among 1151 patients receiving atazanavir 400 mg daily, 177 patients were co-infected with chronic hepatitis B or C, and among 655 patients receiving atazanavir 300 mg daily with ritonavir 100 mg once daily, 97 patients were co-infected with chronic hepatitis B or C. Co-infected patients were more likely to have baseline hepatic transaminase elevations than those without chronic viral hepatitis. No differences in frequency of bilirubin elevations were observed between these patients and those without viral hepatitis. The frequency of treatment emergent hepatitis or transaminase evaluations in co-infected patients was comparable between atazanavir and comparator regimens.

In studies 008 and 034, 74 patients treated with 400 mg of atazanavir once daily, 58 who received efavirenz, and 12 who received nelfinavir were seropositive for hepatitis B and/or C at study entry. AST levels >5 times the upper limit of normal (ULN) developed in 9% of the atazanavir-treated patients, 5% of the efavirenz-treated patients, and 17% of the nelfinavir-treated patients. ALT levels >5 times ULN developed in 15% of the atazanavir-treated patients, 14% of the efavirenz-treated patients, and 17% of the nelfinavir-treated patients. Within atazanavir and control regimens, no difference in frequency of bilirubin elevations was noted between seropositive and seronegative patients.

In study AI424-138, 60 patients treated with atazanavir/ritonavir 300 mg/100 mg once daily, and 51 patients treated with lopinavir/ritonavir 400 mg/100 mg twice daily, each with fixed dose tenofovir-emtricitabine were seropositive for hepatitis B and/or C at study entry. ALT levels > 5 times ULN developed in 10% (6/60) of the atazanavir/ritonavir-treated patients, and 8% (4/50) of the lopinavir/ritonavir-treated patients. AST levels >5 times ULN developed in 10% (6/60) of the atazanavir/ritonavir-treated patients and none (0/50) of the lopinavir/ritonavir-treated patients.

One percent of patients treated with atazanavir experienced concurrent Grade 3-4 ALT/AST and Grade 3-4 total bilirubin elevations.

Effects on lipids

Unlike other protease inhibitors, atazanavir was not associated with clinically important changes from baseline in LDL cholesterol, triglycerides, or total cholesterol mean plasma concentrations. In studies 007, 008, 034, 043, 045 and 138, there were no clinically important changes from baseline in total serum cholesterol, fasting LDL cholesterol, or fasting triglyceride concentrations. Atazanavir had significantly lower mean percent change from baseline in treatment-naïve and protease inhibitor-experienced patients (see Tables 9 and 10).

Lipid changes in treatment-naïve patients receiving combination therapy including atazanavir without ritonavir

Table 9: Lipid – Mean Percentage Changes from Baseline in Atazanavir Clinical Trials in Antiretroviral-naïve Adult Patients

	Study 034 ^a 24 Weeks		Study 008 ^a 48 Weeks		Study 007 ^a 48 Weeks	
	ATV ^c	EFV	ATV ^b	NFV	ATV ^c	NFV
Total Cholesterol	+2% ^{##}	+21%	+5% ^{##}	+25%	+7% ^{##}	+28%
LDL Cholesterol^c	+1% ^{##}	+18%	+5% ^{d, #}	+23% ^d	-7% ^{##}	+31%
HDL Cholesterol	+13% ^{##}	+24%	+12% ^d	+9% ^d	+20%	+16%
Triglycerides^c	-9% ^{##}	+23%	+7% [#]	+50%	+2% [#]	+42%

p < 0.001, ## p < 0.0001

^a NRTI backbone = zidovudine/lamivudine (study 034), lamivudine/stavudine (study 008), didanosine/stavudine (study 007)

^b 400 mg QD

^c Fasting values

^d Week 56

Values are excluded after the start of serum-lipid reduction therapy.
 ATV – atazanavir, EFV – efavirenz, NFV – nelfinavir, LPV - lopinavir

Lipid changes in treatment-naïve patients receiving combination therapy including atazanavir 300 mg with ritonavir 100 mg once daily

Table 10: Lipids - Mean Change from Baseline (Study AI424-138)

	ATV/RTV^{a,b}	LPV/RTV^{b,c}	ATV/RTV - LPV/RTV
	Change^d (%) (n=372^f)	Change^d (%) (n=335^f)	Difference Estimate (95% CI)^e
LDL-Cholesterol^g			
Week 48	+14%	+19%	-4.5% (-8.4%, -0.4%)
Week 96	+14%	+17%	-1.7% (-5.9%, -2.6%)
HDL-Cholesterol^g			
Week 48	+29%	+37%	-5.8% (-9.9%, -1.5%)
Week 96	+21%	+29%	-5.5% (-10%, -0.8%)
Total Cholesterol^g			
Week 48	+13%	+25%	-9.8% (-12.3%, -7.3%)*
Week 96	+13%	+25%	-8.9% (-11.6%, -6.1%)*
Triglycerides^g			
Week 48	+15%	+52%	-24.6% (-29.6%, -19.4%)*
Week 96	+13%	+50%	-24.5% (-29.9%, -18.8%)*

* p < 0.0001

- atazanavir 300 mg plus ritonavir 100 mg once daily with the fixed-dose combination: 300 mg tenofovir, 200 mg emtricitabine once daily.
- Values obtained after initiation of serum lipid-reducing agents were not included in these analyses. Use of serum lipid-reducing agents was more common in the lopinavir/ritonavir treatment arm (8%) than in the atazanavir/ritonavir arm (2%). Through Week 96, serum lipid-reducing agents were used in 10% in the lopinavir/ritonavir treatment arm and 3% in the atazanavir/ritonavir arm.
- Lopinavir 400 mg plus ritonavir 100 mg twice daily with the fixed-dose combination 300 mg tenofovir, 200 mg emtricitabine once daily.
- The change from baseline is the mean of within-patient changes from baseline for patients with both baseline and Week 48 or Week 96 values and is not a simple difference of the baseline and Week 48 or Week 96 mean values, respectively.
- Difference estimates were stratified by qualifying HIV RNA and region.
- Number of patients with LDL-cholesterol measured.
- Fasting

Lipid changes in treatment-experienced patients

The data available on the lipid profile (mean change from baseline) from study 045 are described in the following table (Table 11).

Table 11: AI424045 Lipid Mean Changes from Baseline

	Week 48		Week 96	
	ATV^a/RTV	LPV/RTV	ATV^a/RTV	LPV/RTV
Total Cholesterol	-8%	6%	-7%	9%
LDL Cholesterol^b	-10%	1%	-11%	1%
HDL Cholesterol	-7%	2%	-5%	7%
Triglycerides^b	-4%	30%	-2%	30%

^a 300 mg once daily

^b Fasting values

NRTI backbone: tenofovir disoproxil fumarate + NRTI

Values are excluded after the start of serum-lipid reduction therapy.

ATV – atazanavir, RTV - ritonavir, LPV - lopinavir

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://pophealth.my.site.com/carmreportnz/s/>.

4.9 Overdose

Human experience of acute overdose with atazanavir is limited. Single doses up to 1,200 mg have been taken by healthy volunteers without symptomatic untoward effects. A single self-administered overdose of 29.2 g of atazanavir in an HIV-infected patient (73 times a 400 mg dose) was associated with asymptomatic bifascicular block and PR interval prolongation. These events resolved spontaneously. At high doses that lead to high medicine exposures, jaundice [predominantly due to unconjugated (indirect) hyperbilirubinaemia without associated liver function test changes] or cardiac conduction abnormalities, including PR and/or QT interval prolongations, may be observed (see sections 4.4 and 4.8).

Treatment of overdose with atazanavir should consist of general supportive measures, including monitoring of vital signs and electrocardiogram and observations of the patient's clinical status. Administration of activated charcoal may be used to aid removal of unabsorbed medicine. There is no specific antidote for overdose with atazanavir. Since atazanavir is extensively metabolised by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicine.

For further advice on management of overdose please contact the National Poisons Information Centre (0800 POISON or 0800 764 766).

5. Pharmacological Properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antiviral, protease inhibitor; ATC code: J05AE08

Mechanism of action

Atazanavir is an azapeptide HIV-1 protease inhibitor. The compound selectively inhibits the virus-specific processing of viral gag-pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.

Antiviral activity *in vitro*

Atazanavir exhibits anti-HIV-1 activity (EC_{50} of 2.6 to 5.3 nM) against a variety of HIV isolates in the absence of human serum. Atazanavir administered 400 mg once daily results in a mean (SD) C_{min} of 250 (175) ng/ml. The estimated protein-adjusted (in 40% human serum) C_{min} is approximately 17 to 98 fold higher than a representative EC_{50} . Combinations of atazanavir with stavudine, didanosine, lamivudine, zidovudine, nelfinavir, indinavir, ritonavir, saquinavir, or amprenavir in HIV-infected peripheral blood mononuclear cells yielded additive antiviral effects. Combinations of medicine pairs did not result in antagonistic anti-HIV activity or enhanced cytotoxic effects at the highest concentrations used for antiviral evaluation.

Resistance *in vitro*

HIV-1 isolates with reduced susceptibility to atazanavir (93- to 183-fold resistant) from three different viral strains were selected *in vitro*. The mutations in these HIV-1 viruses that appeared to contribute to atazanavir resistance included N88S, I50L, I84V, A71V, and M46I. Changes were also observed at the protease cleavage sites following medicine selection. The I50L substitution, with or without an A71V substitution, conferred atazanavir resistance in recombinant viral clones in a variety of genetic backgrounds. Recombinant viruses containing the I50L mutation were growth impaired and showed increased susceptibility to other protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir).

Cross-resistance

Atazanavir susceptibility was evaluated *in vitro* using a diverse panel of 551 clinical isolates from patients without prior atazanavir exposure. These isolates exhibited resistance to at least one approved protease inhibitor, with resistance defined as ≥ 2.5 -fold change in EC_{50} relative to a reference strain. Greater than 80% of the isolates resistant to 1 or 2 protease inhibitors (with the majority resistant to nelfinavir) retained susceptibility to atazanavir despite the presence of key mutations (e.g. D30N) associated with protease inhibitor resistance. Of 104 isolates displaying nelfinavir-specific resistance, 84 retained susceptibility to atazanavir. There was a clear trend toward decreased atazanavir susceptibility as isolates exhibited resistance to multiple protease inhibitors. Baseline phenotypic and genotypic analyses of clinical isolates from atazanavir clinical trials of protease inhibitor-experienced subjects showed that isolates cross-resistant to multiple protease inhibitors were also highly cross-resistant (61%-95%) to atazanavir. Greater than 90% of the isolates containing mutations I84V or G48V were resistant to atazanavir. Greater than 60% of isolates containing L90M, A71V/T, M46I, or a change at V82 were resistant to atazanavir, and 38% of isolates containing a D30N mutation in addition to other changes were resistant to atazanavir. Atazanavir-resistant isolates were highly cross-resistant (51%-100%) to other protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir). The I50L and I50V substitutions yielded selective resistance to atazanavir and amprenavir, respectively, and did not appear to confer cross-resistance.

Resistance *in vivo*

Atazanavir-resistant isolates have been obtained from patients experiencing virologic failure on atazanavir therapy.

Clinical studies of treatment-naïve patients receiving atazanavir 400 mg without ritonavir

There were 23 atazanavir-resistant isolates from studies of treatment-naïve patients that showed decreases in susceptibility levels from baseline, and all had evidence of emergence of an I50L substitution on atazanavir therapy (after an average of 50 weeks of therapy) often in combination with an A71V mutation. Phenotypic analysis of the isolates containing the signature mutation I50L showed atazanavir-specific resistance, which coincided with increased susceptibility to other protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir).

Clinical studies of treatment-naïve patients receiving atazanavir 300 mg with ritonavir 100 mg

48 Weeks of Treatment

The Phase III Study AI424138 included 440 patients randomized to atazanavir/ritonavir and 443 patients randomized to lopinavir/ritonavir. Genotypic analysis was undertaken on patients with virologic failure defined as viral rebound ≥ 400 copies/mL or failure to achieve viral suppression <400 copies/mL over 48 weeks of treatment or discontinuation due to insufficient viral load response before 48 weeks. Patients with any major protease inhibitor substitutions at amino acid positions 50, 84 and 88 were determined to have resistance to atazanavir/ritonavir. Patients with any major protease inhibitor substitutions at amino acid positions 32, 48 and 82 were determined to have resistance to lopinavir/ritonavir.

For those patients with virologic failure in the first 48 weeks of the study, baseline genotypic analysis was successful for 25 of 27 atazanavir/ritonavir treated patients and 22 of 26 lopinavir/ritonavir treated patients. Paired baseline and on-study genotypic analysis was successful for 17 of 27 atazanavir/ritonavir treated patients and 15 of 26 lopinavir/ritonavir patients. All patients in both arms of the study had baseline PI substitutions. Major PI substitutions were observed at baseline in two patients; both had phenotypic resistance to both atazanavir/ritonavir and lopinavir/ritonavir and both were randomised to the atazanavir/ritonavir arm of the trial.

While on treatment, one patient with major baseline PI substitutions (I54V, V82A, L90M) developed the atazanavir associated major PI substitution I50L. Another atazanavir/ritonavir treated patient with four baseline atazanavir-associated minor PI substitutions (M36I, I62V, A71A/T and I93L) developed phenotypic resistance to atazanavir along with additional atazanavir-associated minor

substitutions (L10L/F, A71I, G73S). This patient also developed resistance to 3TC/FTC, didanosine, nelfinavir, indinavir, ritonavir, saquinavir and fosamprenavir while remaining sensitive to all other NRTIs, LPV/RTV, tipranavir and darunavir. The isolate remained phenotypically sensitive to TDF despite the presence of K65K/R, K70K/E and M184V.

96 Weeks of Treatment

In Phase III study AI424-138, an as-treated genotypic and phenotypic analysis was conducted on samples from patients who experienced virologic failure ≥ 400 copies/mL or discontinued before achieving suppression on ATV/RTV (n=39; 9%) and LPV/RTV (n=39; 9%) through 96 weeks of treatment. In the ATV/RTV arm, one of the virologic failure isolates had a 56-fold decrease in ATV susceptibility emerge on therapy with the development of PI substitutions L10F, V32I, K43T, M46I, A71I, G73S, I85I/V, and L90M. Five of the treatment failure isolates in the ATV/RTV arm developed emtricitabine resistance with the emergence of either the M184I (1 patient) or the M184V (4 patients) substitution on therapy. In the LPV/RTV arm, one virologic failure isolate had a 69-fold decrease in LPV susceptibility emerge on therapy with the development of PI substitutions L10V and V11I in addition to baseline PI substitutions V32I, I54I/V, V82A, L90M, L10I, A71I, G73S and L89V. Six of the failure isolates in the LPV/RTV arm developed emtricitabine resistance with the emergence of the M184V substitution.

Clinical studies of treatment-experienced patients

In contrast, 30% (18 of 60) of atazanavir-resistant isolates from studies of treatment-experienced patients treated with atazanavir (n=13) or atazanavir plus ritonavir (n=5) showed evidence of an I50L substitution. The remaining 70% (n=42) of isolates with emerging resistance on atazanavir therapy and all 40 resistant isolates from patients on atazanavir plus saquinavir showed no evidence of the emergence of the I50L substitution. Instead, these isolates displayed decreased susceptibility to multiple protease inhibitors and contained mutations associated with resistance to multiple protease inhibitors. These mutations included I84V, L90M, A71V/T, N88S/D, and M46I, which conferred atazanavir resistance and reduced the clinical response to atazanavir.

Generally, if multiple protease inhibitor mutations were present in the HIV-1 of the patient at baseline, atazanavir resistance developed through mutations associated with resistance to other protease inhibitors instead of the I50L mutation. These mutations conferred high cross-resistance to other protease inhibitors with >90% of the isolates resistant to nelfinavir, indinavir, ritonavir, and saquinavir, 83% resistant to lopinavir, and 65% resistant to amprenavir.

In highly treatment-experienced patients receiving atazanavir 300 mg once daily and ritonavir 100 mg once daily (together with tenofovir and an NRTI), the presence at baseline of fewer than four of the protease inhibitor resistance-associated substitutions 10, 20, 24, 33, 36, 46, 48, 54, 63, 71, 73, 82, 84, or 90 was associated with a greater treatment response at Week 48 (70% with HIV RNA <400 copies/mL) than the presence of four or more such substitutions (28% with HIV RNA <400 copies/mL). Genotypic and/or phenotypic analysis of baseline virus may aid in determining atazanavir susceptibility before initiation of atazanavir therapy.

Clinical Trials

Adult Patients without prior antiretroviral therapy

Study AI424138 is a 96 week open-label, randomised, multicenter study of 883 HIV-1 infected treatment-naive patients comparing efficacy and safety of atazanavir/ritonavir (ATV/RTV) 300/100 mg once daily with lopinavir/ritonavir (LPV/RTV) 400/100 mg twice daily each in combination with fixed dose tenofovir/emtricitabine 300/200 once daily. The primary objective of the study was to compare the proportion of patients with HIV RNA < 50 copies/mL at week 48 between ATV/RTV and LPV/RTV. Patient demographic and baseline characteristics were well matched between treatment arms. Overall, patients had a mean age of 36 years (range 19-72), 48% were Caucasian, 18% Black, 9% Asian, 24% Hispanic/ mixed race and 69% were male. The overall median baseline plasma CD4+ cell count was 205 cells/mm³ (range 2 to 810 cells/mm³) and the overall mean baseline plasma HIV-1 RNA level was 4.94 log₁₀ copies/mL (range: 2.60 to 5.88 log₁₀

copies/mL). Treatment response and outcomes through Week 48 and Week 96 are presented in Table 12.

Table 12: Outcomes of Randomised Treatment Through Week 48 and Week 96 (Study AI424-138)

Outcome	Atazanavir 300 mg + ritonavir 100 mg (once daily) with tenofovir/emtricitabine (once daily) ^a (n=440)		Lopinavir 400 mg + ritonavir 100 mg (twice daily) with tenofovir/emtricitabine (once daily) ^a (n=443)	
	48 Weeks	96 Weeks	48 Weeks	96 Weeks
Responder ^b	78% ^c	74% ^d	76% ^c	68% ^d
Virologic failure ^e	14%	12%	12%	12%
Never suppressed through Week 48 or Week 96	9%	2%	6%	1%
Rebound	4%	8%	4%	9%
Discontinued due to insufficient viral load response	1%	3%	2%	2%
Death	1%	1%	<1%	<1%
Discontinued due to adverse event	2%	3%	3%	5%
Discontinued for other reasons ^f	5%	9%	7%	13%

- As a fixed-dose combination: 300 mg tenofovir, 200 mg emtricitabine once daily.
- Patients achieved confirmed HIV RNA <50 copies/mL at week 48. Roche Amplicor®, v1.5 ultra-sensitive assay.
- Pre-specified ITT analysis using as-randomised cohort: ATV/RTV 78% and LPV/RTV 76% [difference estimate: 1.7 (95% confidence interval: -3.8, 7.1)]
- Pre-specified ITT analysis using as-randomised cohort: ATV/RTV 74% and LPV/RTV 68% [difference estimate: 6.1 (95% confidence interval: 0.3, 12.0)].
- Includes viral rebound, discontinued due to insufficient viral load response, and failure to achieve confirmed HIV RNA <50 copies/mL through Week 48 and Week 96 respectively.
- Includes lost to follow-up, patient's withdrawal, non-compliance, protocol violation and other reasons.

The proportion of responders among patients with high viral loads (i.e. baseline HIV RNA \geq 100,000 copies/mL) was comparable for the atazanavir/ritonavir (74% at both 48 weeks and 96 weeks) and lopinavir/ritonavir arms (72% at 48 weeks and 67% at 96 weeks). The median increase from baseline in CD4+ cell count was 191 (48 weeks) and 261 (96 weeks) cells/mm³ for the atazanavir/ritonavir arm and 200 (48 weeks) and 273 (96 weeks) cells/mm³ for the lopinavir/ritonavir arm.

Study 034: Atazanavir once daily compared to efavirenz once daily, each in combination with fixed-dose lamivudine + zidovudine twice daily:

Study AI424-034 was a randomised double-blind, multicenter trial comparing REYATAZ (400 mg once daily) to efavirenz (600 mg once daily), each in combination with a fixed-dose combination of zidovudine (300 mg) and lamivudine (150 mg) given twice daily, in 810 antiretroviral treatment-naïve patients. Patients had a mean age of 34 years (range: 18 to 73), 36% were Hispanic, 33% were Caucasian, and 65% were male. The mean baseline CD4+ cell count was 321 cells/mm³ (range: 64 to 1424 cells/mm³) and the mean baseline plasma HIV-1 RNA level was 4.8 log₁₀ copies /mL (range 2.2 to 5.9 log₁₀ copies/mL). Treatment response and outcomes through week 48 are presented in Table 13.


Table 13: Treatment Outcome at Week 48 - Treated Subjects (AI424034)

	Atazanavir 400 mg once daily + lamivudine + zidovudine (N = 404)	Efavirenz 600 mg once daily + lamivudine + zidovudine (N = 401)
Responder ^a	67% [31%] ^b	63% [36%]
Virologic failure ^c	20%	19%
Never suppressed through Week 48	7%	7%
Rebound	13%	11%
Death ^d	0%	<1%
Disease progression	<1%	<1%
Discontinued due to adverse event ^e	6%	9%
Discontinued due to other reason	6%	9%

- a. Responders achieved and maintained to Week 48 2 consecutive HIV RNA < 400 c/mL.
- b. Percentages in brackets represent responders who achieved and maintained to Week 48 at least 2 consecutive HIV RNA < 50 c/mL.
- c. Virologic failure includes rebound (ie, 2 consecutive HIV RNA ≥ 400 c/mL or last HIV RNA ≥ 400 c/mL) and failing to achieve confirmed HIV RNA < 400 c/mL through Week 48.
- d. All deaths were not considered related to study therapy
- e. 23 of the 26 subjects on ATV, and 33 of the 36 subjects on EFV who discontinued due to AEs did so for reasons considered related to study medicine.


The mean increase from baseline in CD4+ cell count was 176 cells/mm³ for the atazanavir arm and 160 cells/mm³ for the efavirenz arm.

Figure 1. Response through 48 weeks for patients treated with atazanavir (ATV) or efavirenz (EFV) in Study 034 (patients without prior antiretroviral experience)



Study 008 was a 48-week study of two doses of atazanavir 400 mg once daily (n = 181) or 600 mg once daily (n = 195) compared to nelfinavir 1,250 mg BID (n = 91) in combination with stavudine (40 mg) and lamivudine (150 mg) twice daily. At baseline, mean HIV RNA levels were 4.74 log₁₀ copies/mL and 4.73 log₁₀ copies/mL for the atazanavir 400 mg and nelfinavir groups, respectively. The mean CD4 counts at baseline were 294 cells/mm³ and 283 cells/mm³ for the atazanavir 400 mg and nelfinavir groups, respectively. Results from this study are shown in Figure 2 and Table 14.

Figure 2. Observed response through 48 weeks of treatment with atazanavir (ATV) 400 mg or nelfinavir (NFV) in Study 008 (patients without prior antiretroviral experience)



Weeks	ATV 400: Number with measurements	NFV: Number with measurements
B/L	181	91
4	178	91
8	174	91
12	172	89
16	171	88
24	171	86
32	169	86
40	162	82
48	156	80

Table 14: Outcomes of Treatment in Study 008 through Week 48 (Patients without Prior Antiretroviral Experience)^a

	ATV ^b 400 mg	NFV
Randomised Patients	n = 181	n = 91
Percent with HIV RNA < 400 copies/ml ^c	64%	53%
ATV-Control Treatment Difference (95% CI)	11.0% (-1.1, 23.2)	
Patients Completing 48 Weeks of Treatment	n = 156	n = 80
Percent with HIV RNA < 400 copies/ ml ^c	74%	60%
ATV-Control Treatment Difference (95% CI)	13.8% (1.6, 26.1)*	
HIV RNA Mean Change from Baseline (log ₁₀ copies/mL) ^{c,d}	-2.51	-2.31
CD4 Mean change from Baseline (cells/mm ³) at Week 48	234	211

* p < 0.05

a NRTI backbones = 3TC/d4T (study 008)

b 400 mg once daily

c Roche Ultra Sensitive Amplicor® HIV-1 Monitor assay, version 1.0 or 1.5, as appropriate

d Protocol-defined primary outcome measure

ATV – atazanavir, NFV – nelfinavir, CI – 95% confidence intervals.

Adult Patients with prior antiretroviral therapy

Study 045 is a randomised, multicenter trial comparing atazanavir (300 mg once daily) with ritonavir (100 mg once daily) to atazanavir (400 mg once daily) with saquinavir soft gelatine capsules (1,200 mg once daily), and to lopinavir + ritonavir (400/100 mg fixed dose combination twice daily), each in combination with tenofovir and one NRTI, in 347 (of 358 randomised) patients with virologic failure on two or more prior regimens containing at least one PI, NRTI, and NNRTI. For randomised patients, the mean time of prior antiretroviral exposure was 138 weeks for PIs, 280 weeks for NRTIs, and 85 weeks for NNRTIs. The mean baseline CD4 cell count was 336 cells/mm³ (range: 14 to 1,543

cells/mm³) and the mean baseline plasma HIV-1 RNA level was 4.4 log₁₀ copies/ml (range: 2.6 to 5.9 log₁₀ copies/ml).

The primary endpoint for this study is the time-averaged difference in change from baseline in HIV RNA through 24 weeks and 48 weeks. Results from this study for the atazanavir and ritonavir and lopinavir + ritonavir treatment arms are shown in Table 15.

Through the 48 weeks of treatment, the decreases from baseline in HIV RNA levels (primary endpoint) were 1.93 log₁₀ copies/mL for atazanavir + ritonavir and 1.87 log₁₀ copies/mL for lopinavir + ritonavir. The primary endpoint was time-averaged difference in HIV RNA levels, atazanavir + ritonavir minus lopinavir + ritonavir (97.5% Confidence Intervals). Atazanavir + ritonavir was considered to be non-inferior if the upper 97.5% CI for the TAD was less than 0.5 log₁₀ copies/mL.

At 48 weeks, non-inferiority was demonstrated. The time averaged difference in HIV RNA was 0.13 (-0.12; 0.39). The mean decrease from baseline HIV RNA levels for atazanavir + ritonavir was 1.93 log₁₀ copies/mL. For lopinavir + ritonavir the decrease was 1.87 log₁₀ copies/mL.

At 96 weeks the time-averaged difference in HIV RNA levels was 0.14 (-0.13; 0.41). The mean decrease from baseline HIV RNA levels for atazanavir + ritonavir was 2.29 log₁₀ copies/mL, and for lopinavir + ritonavir the mean decrease was 2.08 log₁₀ copies/mL. Durability of efficacy was demonstrated. Further outcomes of treatment are shown in Table 15.

Table 15: AI424045 Efficacy Endpoints – Adult Randomized Subjects

	Week 48		Week 96	
	ATV/RTV ^a N = 120	LPV/RTV N = 123	ATV/RTV N = 120	LPV/RTV N = 123
HIV RNA < 400 c/mL ^{b,c}	53%	54%	43%	46%
HIV RNA < 50 c/mL ^{b,c}	36%	42%	32%	35%
CD4 cell count mean change from baseline (cells/mm ³)	110	121	122	154

a. Atazanavir 300 mg with ritonavir 100 mg once daily

b. Subjects achieved and maintained 2 consecutive HIV RNA < 400 (50) c/mL through the analysis week. Subjects who completed the study were censored in the Week 96 analyses.

c. Roche Amplicor® Ultra Sensitive HIV-1 Monitor Assay; version 1.0 or 1.5 as appropriate.

ATV – atazanavir; LPV – lopinavir; RTV - ritonavir

Response to treatment assessed as HIV RNA change from baseline was analysed by baseline genotypic mutation at 48 weeks. Patients who had four or more of the following mutations 10, 20, 24, 32, 33, 36, 46, 68, 50, 54, 63, 71, 73, 82, 84, 90 were considered. The results significantly favoured the lopinavir + ritonavir arm.

Atazanavir plus saquinavir was shown to be inferior to lopinavir plus ritonavir.

Adult patients co-infected with hepatitis B and/or hepatitis C

Analyses have been performed that compare outcomes in study 008 for those patients without baseline evidence of either chronic HBV or HCV infection with those with chronic HBV and/or HCV. Virologic suppression was comparable for the atazanavir 400 mg once daily patients, regardless of chronic hepatitis status. The Week 48 mean change from baseline in HIV RNA for 19 chronic hepatitis positive patients was -2.46 log₁₀ copies/mL, comparable to -2.51 log₁₀ copies/mL for 132 hepatitis negative patients.

In study AI424-138, 42 of 61 patients (69%) co-infected with HBV and/or HCV, achieved confirmed HIV RNA <50 copies/mL at week 48. Among hepatitis negative patients, 300 of 378 (79%) achieved confirmed HIV RNA <50 copies/mL at week 48.

Children - PACTG 1020A

Assessment of the pharmacokinetics, safety, tolerability, and efficacy of atazanavir is based on data from the open-label, multicentre clinical trial PACTG 1020A conducted in patients from 3 months to 21 years of age. In this study, 105 patients (43 antiretroviral-naïve and 62 antiretroviral-experienced) received atazanavir once daily, with or without ritonavir, in combination with two NRTIs. Using an ITT analysis, the overall proportions of antiretroviral-naïve and –experienced patients with HIV RNA <400 copies/mL at Week 96 were 51% (22/43) and 34% (21/62), respectively. The overall proportions of antiretroviral-naïve and –experienced patients with HIV RNA <50 copies/mL at Week 96 were 47% (20/43) and 24% (15/62), respectively. The median increase from baseline in absolute CD4 count at 96 weeks of therapy was 335 cells/mm³ in antiretroviral-naïve patients and 220 cells/mm³ in antiretroviral-experienced patients.

5.2 Pharmacokinetic properties

The pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV-infected adult and paediatric patients.

Healthy adult volunteers and HIV-infected patients

The pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV-infected patients after administration of atazanavir 400 mg once daily and after administration of atazanavir 300 mg with ritonavir 100 mg once daily (see Table 16).

Table 16: Steady-State Pharmacokinetics of Atazanavir in Healthy Subjects or HIV- Infected Patients in the Fed State

Parameter	400 mg once daily		300 mg with ritonavir 100 mg once daily	
	Healthy Subjects (n=14)	HIV-Infected Patients (n=13)	Healthy Subjects (n=28)	HIV-Infected Patients (n=10)
C_{max} (ng/mL)				
Geometric mean (CV%)	5199 (26)	2298 (71)	6129 (31)	4422 (58)
Mean (SD)	5358 (1371)	3152 (2231)	6450 (2031)	5233 (3033)
T_{max} (h)				
Median	2.5	2.0	2.7	3.0
AUC (ng·h/mL)				
Geometric mean (CV%)	28132 (28)	14874 (91)	57039 (37)	46073 (66)
Mean (SD)	29303 (8263)	22262 (20159)	61435 (22911)	53761 (35294)
T-half (h)				
Mean (SD)	7.9 (2.9)	6.5 (2.6)	18.1 (6.2) ^a	8.6 (2.3)
C_{min} (ng/mL)				
Geometric mean (CV%)	159 (88)	120 (109)	1227 (53)	636 (97)
Mean (SD)	218 (191)	273 (298) ^b	1441 (757)	862 (838)

a. n=26

b. n=12

C_{max} – maximum plasma medicine concentration during a dosing interval

C_{min} – minimum plasma medicine concentration during a dosing interval

AUC – total area under the plasma medicine concentration-time curve

T_{max} – time to maximum concentration

T-half – Half life; CV% - percent coefficient of variation

SD - standard deviation

Absorption

The T_{max} of atazanavir is approximately 2.5 hours. Atazanavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC and C_{max} values over the dose range of 200-800 mg once daily. Steady-state is achieved between Days 4 and 8, with an accumulation of approximately 2.3-fold.

Food effect

Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability. Administration of a single 400 mg dose of atazanavir with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) (i.e. toast with jam, low fat margarine, orange juice and skim milk) resulted in a 70% increase in AUC and a 57% increase in C_{max} compared to the fasting state. Administration of a single 400 mg dose of atazanavir (as two 200 mg capsules) with a meal high in calories, fat, and protein (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% and no change in C_{max} compared to administration in the fasting state. Administration of atazanavir with either a light meal or a high fat meal decreased the coefficient of variation of AUC and C_{max} approximately one-half compared to the fasting state.

Co-administration of a single 300 mg dose of atazanavir and a 100 mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the C_{max} and the 24-hour concentration of atazanavir relative to the fasting state. Co-administration with a high-fat meal (951 kcal, 54.7 g fat, 35.9 g protein) did not affect the AUC of atazanavir relative to fasting conditions and the C_{max} was within 11% of fasting values. The 24-hour concentration following a high-fat meal was increased by approximately 33% due to delayed absorption; the median T_{max} increased from 2.0 to 5.0 hours. Co-administration of atazanavir with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and C_{max} by approximately 25% compared to the fasting state.

To enhance bioavailability and minimise variability, atazanavir is to be taken with food.

Distribution

Atazanavir was approximately 86% bound to human serum proteins over a concentration range of 100 to 10,000 ng/ml. Atazanavir binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively, at 1,000 ng/ml).

Metabolism

Studies in humans and *in vitro* studies using human liver microsomes have demonstrated that atazanavir is principally metabolised by CYP3A4 isozyme to oxygenated metabolites which are then excreted in the bile as either free or glucuronidated metabolites. Additional minor metabolic pathways consist of N-dealkylation and hydrolysis. Two metabolites of atazanavir, possessing no anti-HIV activity, have been detected in the systemic circulation.

Elimination

Following a single 400 mg dose of ^{14}C -atazanavir, 79% and 13% of the total radioactivity was recovered in the faeces and urine, respectively. Approximately 26% of the radioactivity in the faeces was due to parent medicine, corresponding to 20% of the dose, and 44% of the radioactivity in the urine was due to parent medicine, corresponding to 7% of the dose. The mean elimination half-life of atazanavir in healthy volunteers and HIV-infected patients adult patients was approximately 7 hours at steady state following a dose of 400 mg daily with a light meal.

Special populations

Impaired renal function

In healthy subjects, the renal elimination of unchanged atazanavir was approximately 7% of the administered dose. Atazanavir has been studied in adult subjects with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily. The mean atazanavir C_{max} was 9% lower, AUC was 19% higher, and C_{min} was 96% higher in subjects with

severe renal impairment not undergoing haemodialysis (n=10), than in age, weight, and gender matched subjects with normal renal function. Atazanavir was not appreciably cleared during haemodialysis. In a 4-hour dialysis session, 2.1% of the administered dose was removed. When atazanavir was administered either prior to, or following haemodialysis (n=10), the geometric means for C_{max} were 25% and 37% lower, AUC were 28% and 42% lower, and C_{min} were 43% and 54% lower, respectively, compared to subjects with normal renal function. The mechanism of this decrease is unknown (see section 4.2).

Impaired hepatic function

Atazanavir is metabolised and eliminated primarily by the liver. Atazanavir has been studied in adult patients with moderate to severe hepatic impairment after a single 400 mg dose. The mean AUC (0-∞) was 42% greater in patients with impaired hepatic function than in healthy volunteers. The mean half-life of atazanavir in hepatically impaired patients was 12.1 hours compared to 6.4 hours in healthy volunteers (see sections 4.2, 4.3 and 4.4).

Age/gender

A study of the pharmacokinetics of atazanavir was performed in 59 healthy male and female adult subjects (29 young, 30 elderly). There were no clinically significant differences in AUC or C_{max} based on age or gender in this study.

Paediatric Patient Pharmacokinetics

Children and adolescents (6 – 18 years of age)

The pharmacokinetic data from paediatric patients receiving atazanavir capsules with ritonavir based on body surface area are presented in Table 17.

Table 17: Steady-State Pharmacokinetics of Atazanavir with ritonavir in HIV-Infected Paediatric Patients (6 to 18 years of age) in the Fed State		
205 mg/m² atazanavir with 100 mg/m² ritonavir once daily		
Age Range (years)		
	at least 6 to 13 (n=17)	at least 13 to 18 (n=10)
Dose mg		
Median	200	400
[min-max]	[150–400]	[250–500]
C_{max} ng/mL		
Geometric Mean (CV%)	4451 (33)	3711 (46)
AUC ng•h/mL		
Geometric Mean (CV%)	42503 (36)	44970 (34)
C_{min} ng/mL		
Geometric Mean (CV%)	535 (62)	1090 (60)

Table 18 presents the pharmacokinetics for atazanavir at steady state in paediatric patients predicted by a pharmacokinetic model, summarised by weight ranges that correspond to the recommended doses (see section 4.2).

Table 18: Predicted Steady-State Pharmacokinetics of Atazanavir (Capsule Formulation) with Ritonavir in HIV-Infected Paediatric Patients			
Parameter	atazanavir 150 mg/ ritonavir 100 mg	atazanavir 200 mg/ ritonavir 100 mg	atazanavir 300 mg/ ritonavir 100 mg
	Body weight (range in kg) 15 - <20	Body weight (range in kg) 20 - <40	Body weight (range in kg) ≥ 40
C_{max} ng/mL			
Geometric Mean (CV%)	5213 (78.7%)	4954 (81.7%)	5040 (84.6%)

AUC ng•h/mL			
Geometric Mean (CV%)	42902 (77.0%)	42999 (78.5%)	46777 (80.6%)
C _{min} ng/mL			
Geometric Mean (CV%)	504 (99.5%)	562 (98.9%)	691 (98.5%)

Atazanavir exposures were predicted based on observed data in 167 paediatric patients and 60 adult patients treated with atazanavir with or without ritonavir. See section 4.4 regarding inter-patient variability in atazanavir exposure parameters.

Children less than 6 years of age

There are no dosing recommendations for atazanavir in paediatric patients less than 6 years of age as there is insufficient data to recommend a dose. Atazanavir should not be administered to paediatric patients below 3 months of age due to the risk of kernicterus.

Pregnancy

The pharmacokinetic data from HIV-infected pregnant women receiving atazanavir capsules with ritonavir are presented in Table 19.

Table 19: Steady-State Pharmacokinetics of Atazanavir with ritonavir in HIV- infected Pregnant Women in the Fed State

atazanavir 300 mg with ritonavir 100 mg				
Pharmacokinetic	2nd Trimester	3rd Trimester	Historical Non-Pregnant ^a	Postpartum ^b
Parameter	(n=9)	(n=20)	(n=23)	(n=36)
C _{max} ng/mL				
Geometric Mean (CV%)	3729.09 (39)	3291.46 (48)	4485.18 (32)	5649.10 (31)
AUC ng•h/mL				
Geometric Mean (CV%)	34399.1 (37)	34251.5 (43)	43888.06 (42)	60532.7 (33)
C _{min} ng/mL ^c				
Geometric Mean (CV%)	663.78 (36)	668.48 (50)	661.50 (67)	1420.64 (47)

a Atazanavir peak concentration and AUCs were found to be approximately 17-27% lower during pregnancy relative to those observed historically in HIV-infected, non-pregnant patients. Atazanavir plasma trough concentrations were similar when compared to those observed historically in HIV-infected, non-pregnant patients.

b Atazanavir peak concentrations and AUCs were found to be approximately 26-40% higher during postpartum period (4-12 weeks) than those observed historically in HIV-infected, non-pregnant patients. Atazanavir plasma trough concentrations were approximately 2-fold higher during postpartum period when compared to those observed historically in HIV-infected, non-pregnant patients.

c C_{min} is concentration 24 hours post-dose.

Medicine interactions

Atazanavir is metabolized in the liver by CYP3A4. Atazanavir inhibits CYP3A4 and UGT1A1 at clinically relevant concentrations with K_i of 2.35 µM (CYP3A4 isoform) and 1.9 µM, respectively. Atazanavir is a metabolism-dependent CYP3A inhibitor, with a K_{inact} value of 0.05 to 0.06 min⁻¹ and K_i value of 0.84 to 1.0µM. Atazanavir is also a direct inhibitor for UGT1A1 (K_i=1.9µM) and CYP2C8 (K_i=2.1µM). Atazanavir should not be administered concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4 or UGT1A1 (see sections 4.3 and 4.4).

Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2 or CYP2E1.

Atazanavir is a weak inhibitor of CYP2C8. Caution should be used when atazanavir without ritonavir is co-administered with medicines highly dependent on CYP2C8 with narrow therapeutic indices

(e.g. paclitaxel, repaglinide). When atazanavir with ritonavir is co-administered with substrates of CYP2C8, clinically significant interactions are not expected.

Atazanavir has been shown *in vivo* not to induce its own metabolism, nor to increase the biotransformation of some medicines metabolized by CYP3A4. In a multiple-dose study, atazanavir decreased the urinary ratio of endogenous 6 β -OH cortisol to cortisol versus baseline, indicating that CYP3A4 production was not induced.

Medicines that induce CYP3A4 activity may increase the clearance of atazanavir, resulting in lowered plasma concentrations. Co-administration of atazanavir and other medicines that inhibit CYP3A4 may increase atazanavir plasma concentrations.

Medicine interaction studies were performed with atazanavir and other medicines likely to be co-administered and some medicines commonly used as probes for pharmacokinetic interactions. The effects of co-administration of atazanavir on the AUC, C_{max}, and C_{min} are summarized in Tables 20 and 21. For information regarding clinical recommendations, see sections 4.3 and 4.4.

Table 20: Medicine Interactions: Pharmacokinetic Parameters for Atazanavir in the Presence of Co-administered Medicines^a

Co-administered Medicine	Co-administered Medicine Dose/Schedule	Atazanavir Dose Schedule	n	Ratio (90% Confidence Interval) of Atazanavir Pharmacokinetic Parameters with/without Co-administered Medicine; No Effect = 1.00		
				C _{max}	AUC	C _{min}
atenolol	50 mg once daily, d 7-11 and d 19-23	400 mg once daily, d 1-11	19	1.00 (0.89, 1.12)	0.93 (0.85, 1.01)	0.74 (0.65, 0.86)
clarithromycin	500 mg BID, d 7-10 and d 18-21	400 mg once daily, d 1-10	29	1.06 (0.93, 1.20)	1.28 (1.16, 1.43)	1.91 (1.66, 2.21)
didanosine (ddl) (buffered tablets) plus stavudine (d4T) ^b	ddl: 200 mg x 1 dose, d4T: 40 mg x 1 dose	400 mg x 1 dose simultaneously with ddl and d4T	31	0.11 (0.06, 0.18)	0.13 (0.08, 0.21)	0.16 (0.10, 0.27)
	ddl: 200 mg x 1 dose, d4T: 40 mg x 1 dose	400 mg x 1 dose 1 hour after ddl + d4T	32	1.12 (0.67, 1.18)	1.03 (0.64, 1.67)	1.03 (0.61, 1.73)
didanosine (ddl) (enteric coated capsules) ^c	400 mg d 8 (fed)	400 mg x 1 dose d 2-8	34	1.03 (0.93, 1.14)	0.99 (0.91, 1.09)	0.98 (0.89, 1.08)
	400 mg d 19 (fed)	300 mg/ritonavir 100 mg x 1 dose d 9-19	31	1.04 (1.01, 1.07)	1.00 (0.96, 1.03)	0.87 (0.82, 0.92)
diltiazem	180 mg once daily, d 7-11 and d 19-23	400 mg once daily, d 1-11	30	1.04 (0.96, 1.11)	1.00 (0.95, 1.05)	0.98 (0.90, 1.07)
efavirenz	600 mg once daily, d 7-20	400 mg once daily, d 1-20	27	0.41 (0.33, 0.51)	0.26 (0.22, 0.32)	0.07 (0.05, 0.10)
	600 mg once daily d 7 - 20	400 mg once daily, d 1-6 then 300 mg/ritonavir 100 mg once daily, 2 h before efavirenz d 7-20	23 (d1-6) 13 (d7-20)	1.14 (0.83, 1.58)	1.39 (1.02, 1.88)	1.48 (1.24, 1.76)
	600 mg once daily d 11-24 (PM)	300 mg once daily/ ritonavir 100 mg once daily, d 1-10 (pm), then 400 mg once daily/ ritonavir 100 mg once daily, d 11-24 (pm), (simultaneous with efavirenz)	14	1.17 (1.08, 1.27)	1.00 (0.91, 1.10)	0.58 (0.49, 0.69)
famotidine	40 mg BID d 7-12	400 mg once daily d 1-12 (simultaneous administration)	15	0.53 (0.34, 0.82)	0.59 (0.40, 0.87)	0.58 (0.37, 0.89)

	40 mg BID d 7-12	400 mg once daily (pm) d 1-6, d 7-12 (10 hr after, 2 hr before famotidine)	45 (d1-6) 14 (d7-12)	1.08 (0.82, 1.41)	0.95 (0.74, 1.21)	0.79 (0.06, 1.04)
	40 mg BID d 11-20	300 mg once daily/ritonavir 100 mg once daily d 1- 20 ^d (simultaneous administration)	14	0.86 (0.79, 0.94)	0.82 (0.75, 0.89)	0.72 (0.64, 0.81)
	20 mg BID, d 11-17	300 mg once daily/ritonavir 100 mg once daily/tenofovir 300 mg once daily, d 1- 10 (am), d 11-17 (am) simultaneous administration with am famotidine)	39 (d1-10) 18 ^{e,f} (d11-17)	0.91 (0.84, 0.99)	0.90 (0.82, 0.98)	0.81 (0.69, 0.94)
	40 mg once daily (pm), d 18-24	300 mg once daily/ritonavir 100 mg once daily/tenofovir 300 mg once daily d 1- 10 (am), d 18-24 (am) (12 h after pm famotidine)	39 (d1-10) 20 (d18- 24) ^f	0.89 (0.81, 0.97)	0.88 (0.80, 0.96)	0.77 (0.63, 0.93)
	40 mg BID, d 18-24	300 mg once daily/ritonavir 100 mg once daily/tenofovir 300 mg once daily, d 1- 10 (am), d 18-24 (am) (10 h after pm famotidine and 2 h before am famotidine)	39 (d1-10) 18 (d18- 24) ^f	0.74 (0.66, 0.84)	0.79 (0.70, 0.88)	0.72 (0.63, 0.83)
	40 mg BID, d 11-20	300 mg once daily/ritonavir 100 mg once daily, d 1- 10 (am) , then 400 mg once daily/ritonavir 100 mg once daily, d 11-20	46 (d1-10) 15 (d11-20)	1.02 (0.87, 1.18)	1.03 (0.86, 1.22)	0.86 (0.68, 1.08)
fluconazole	200 mg once daily, d 11–20	300 mg once daily/ritonavir 100 mg once daily, d 1– 10, then 300 mg once daily/ritonavir 100 mg one daily, d 11– 20	29	1.03 (0.95, 1.11)	1.04 (0.95, 1.13)	0.98 (0.85, 1.13)
ketoconazole	200 mg once daily, d 7-13	400 mg once daily, d 1-13	14	0.99 (0.77, 1.28)	1.10 (0.89, 1.37)	1.03 (0.53, 2.01)

nevirapine ^{g,h}	200 mg BID, d 1–23	300 mg once daily/ritonavir 100 mg once daily, d 4–13, then 400 mg once daily/ritonavir 100 mg once daily, d 14–23 ⁱ	23	0.72 (0.60, 0.86)	0.58 (0.48, 0.71)	0.28 (0.20, 0.40)
				1.02 (0.85, 1.24)	0.81 (0.65, 1.02)	0.41 (0.27, 0.60)
omeprazole	40 mg once daily d 7-12 ⁱ	400 mg once daily d 1-6, d 7-12	48 (d1-6) 16 (d7-12)	0.04 (0.04, 0.05)	0.06 (0.05,0.07)	0.05 (0.03, 0.07)
		300 mg once daily/ritonavir 100 mg once daily d 1-20	15	0.28 (0.24, 0.32)	0.24 (0.21, 0.27)	0.22 (0.19, 0.26)
		300 mg once daily/ritonavir 100 mg once daily, d 7-16 (pm), d 17-23 (pm)	27 (d7-16) 13 (d17-23) ^{k,l}	0.61 (0.46, 0.81)	0.58 (0.44, 0.75)	0.54 (0.41, 0.71)
		300 mg once daily/ritonavir 100 mg once daily, d 7-16 (am), then 400 mg once daily/ritonavir 100 mg once daily, d 17-23	27 (d7-16) 14 (d17-23) ^{m,n}	0.69 (0.58, 0.83)	0.70 (0.57, 0.86)	0.69 (0.54, 0.88)
rifabutin	150 mg once daily, d 15-28	400 mg once daily, d 1-28	7	1.34 (1.14, 1.59)	1.15 (0.98, 1.34)	1.13 (0.68, 1.87)
rifampicin	600 mg once daily d 17-26	300 mg once daily/ritonavir 100 mg once daily	16	0.47 (0.41, 0.53)	0.28 (0.25, 0.32)	0.02 (0.02, 0.03)
ritonavir ^o	100 mg once daily, d 11-20	300 mg once daily, d 1-20	28	1.86 (1.69, 2.05)	3.38 (3.13, 3.63)	11.89 (10.23, 13.82)
tenofovir ^{p,q}	300 mg once daily with food d 9-16	400 mg once daily with food d 2-16	34	0.79 (0.73, 0.86)	0.75 (0.70, 0.81)	0.60 (0.52, 0.68)
tenofovir ^{p,q}	tenofovir 300 mg once daily d 15-42	300 mg once daily with ritonavir 100 mg once daily d 1-42	10	0.72 ^r (0.50, 1.05)	0.75 ^r (0.58, 0.97)	0.77 ^r (0.54, 1.10)
voriconazole ^s (subjects with at least one functional CYP2C19 allele)	200 mg BID, d 2-3, 22-30;	300 mg/ritonavir 100 mg QD, d 11-30	20	0.87 (0.80, 0.96)	0.88 (0.82, 0.95)	0.80 (0.72, 0.90)
	400 mg BID, d 1, 21					
voriconazole ^s (subjects without a functional CYP2C19 allele)	50 mg BID, d 2-3, 22-30;	300 mg/ritonavir 100 mg QD, d 11-30	8	0.81 (0.66, 1.00)	0.80 (0.65, 0.97)	0.69 (0.54, 0.87)
	100 mg BID, d 1, 21					

-
- a. Data provided are under fed conditions unless otherwise noted.
 - b. All medicines were given under fasted conditions.
 - c. 400 mg didanosine enteric-coated capsules and atazanavir were administered together with food on days 8 and 19.
 - d. Atazanavir 300 mg plus ritonavir 100 mg once daily co-administered with famotidine 40 mg twice daily resulted in atazanavir geometric mean C_{max} that was similar and AUC and C_{min} values that were 1.79- and 4.46-fold higher relative to atazanavir 400 mg once daily alone.
 - e. Similar results were noted when famotidine 20 mg BID was administered 2 hours after and 10 hours before atazanavir 300 mg and ritonavir 100 mg plus tenofovir 300 mg.
 - f. Atazanavir/ritonavir/tenofovir was administered after a light meal.
 - g. Study was conducted in HIV-infected individuals.
 - h. Compared with atazanavir 400 mg historical data without nevirapine (n=13), the ratio of geometric means (90% confidence intervals) for C_{max} , AUC, and C_{min} were 1.42 (0.98, 2.05), 1.64 (1.11, 2.42), and 1.25 (0.66, 2.36), respectively, for atazanavir/ritonavir 300/100 mg; and 2.02 (1.42, 2.87), 2.28 (1.54, 3.38), and 1.80 (0.94, 3.45), respectively, for atazanavir/ritonavir 400/100 mg.
 - i. Parallel group design; n=23 for atazanavir/ritonavir plus nevirapine, n=22 for atazanavir 300 mg/ritonavir 100 mg without nevirapine. Subjects were treated with nevirapine prior to study entry.
 - j. Omeprazole 40 mg was administered on an empty stomach 2 hours before atazanavir.
 - k. Omeprazole 20 mg was administered 30 minutes prior to a light meal in the morning and atazanavir 300 mg plus ritonavir 100 mg in the evening after a light meal, separated by 12 hours from omeprazole.
 - l. Atazanavir 300 mg plus ritonavir 100 mg once daily separated by 12 hours from omeprazole 20 mg daily resulted in increases in atazanavir geometric mean AUC (10%) and C_{min} (2.4-fold), with a decrease in C_{max} (29%) relative to atazanavir 400 mg once daily in the absence of omeprazole (study days 1-6).
 - m. Omeprazole 20 mg was given 30 min prior to a light meal in the morning and atazanavir 400 mg plus ritonavir 100 mg once daily after a light meal, 1 hour after omeprazole. Effects on atazanavir concentrations were similar when atazanavir 400 mg plus ritonavir was separated from omeprazole 20 mg by 12 hours.
 - n. Atazanavir 400 mg plus ritonavir 100 mg once daily administered with omeprazole 20 mg once daily resulted in increases in atazanavir geometric mean AUC (32%) and C_{min} (3.3-fold), with a decrease in C_{max} (26%) relative to atazanavir 400 mg once daily in the absence of omeprazole (study days 1-6).
 - o. Compared with atazanavir 400 mg once daily historical data, administration of atazanavir/ritonavir 300/100 mg once daily increased the atazanavir geometric mean values of C_{max} , AUC, and C_{min} by 18%, 103%, and 671%, respectively.
 - p. Tenofovir disoproxil fumarate.
 - q. Note that similar results were observed in studies where administration of tenofovir and atazanavir were separated by 12 hours.
 - r. Ratio of atazanavir plus ritonavir plus tenofovir to atazanavir plus ritonavir. Atazanavir 300 mg plus ritonavir 100 mg results in higher atazanavir exposure than atazanavir 400 mg (see footnote o). The geometric mean values of atazanavir pharmacokinetic parameters when co-administered with ritonavir were: C_{max} =3190 ng/mL, AUC = 34459 ng•h/mL and C_{min} = 491 ng/mL. Study was conducted in HIV-infected individuals.
 - s. Refer also to Table 3 (see section 4.5)

AUC = area under the [concentration-time] curve; BID = twice daily; C_{max} = maximum plasma concentration; C_{min} = minimum plasma concentration; d = day; h = hour; mg = milligram; n = number.

Table 21: Medicine Interactions: Pharmacokinetic Parameters for Co-administered Medicines in the Presence of Atazanavir^a

Co-administered Medicine	Co-administered Medicine Dose/Schedule	Atazanavir Dose Schedule	n	Ratio (90% Confidence Interval) of Co-administered Medicine Pharmacokinetic Parameters with/without Atazanavir; No Effect = 1.00		
				C _{max}	AUC	C _{min}
paracetamol	1 gm BID, d 1-20	300 mg once daily/ritonavir 100 mg once daily, d 11-20	10	0.87 (0.77, 0.99)	0.97 (0.91, 1.03)	1.26 (1.08, 1.46)
atenolol	50 mg once daily, d 7-11 and d 19-23	400 mg once daily, d 1-11	19	1.34 (1.26, 1.42)	1.25 (1.16, 1.34)	1.02 (0.88, 1.19)
clarithromycin	500 mg BID, d 7-10 and d 18-21	400 mg once daily, d 1-10	21	1.50 (1.32, 1.71)	1.94 (1.75, 2.16)	0.38 (0.35, 0.43)
didanosine (ddl) (buffered tablets) plus stavudine (d4T) ^b	ddl: 200 mg x 1 dose, d4T: 40 mg x 1 dose	400 mg x 1 dose simultaneous with ddl and d4T	31	OH-clarithromycin: 0.28 (0.24, 0.33) ddl: 0.92 (0.84, 1.02) d4T: 1.08 (0.96, 1.22)	OH-clarithromycin: 0.30 (0.26, 0.34) ddl: 0.98 (0.92, 1.05) d4T: 1.00 (0.97, 1.03)	OH-clarithromycin: 2.64 (2.36, 2.94) NA d4T: 1.04 (0.94, 1.16)
didanosine enteric coated capsules ^c	400 mg d 1 (fasted), 8 (fed)	400 mg once daily d 2-8	34	0.64 (0.55, 0.74)	0.66 (0.60, 0.74)	1.13 (0.91, 1.41)
	400 mg d 1 (fasted) 19 (fed)	300 mg once daily/ritonavir 100 mg once daily d 9-19	31	0.62 (0.52, 0.74)	0.66 (0.59, 0.73)	1.25 (0.92, 1.69)
diltiazem	180 mg once daily, d 7-11 and d 19-23	400 mg once daily, d 1-11	28	1.98 (1.78, 2.19) desacetyl-diltiazem: 2.72 (2.44, 3.03)	2.25 (2.09, 2.16) desacetyl-diltiazem: 2.65 (2.45, 2.87)	0.41 (0.37, 0.47) desacetyl-diltiazem: 0.45 (0.41, 0.49)
ethinyl estradiol & norethindrone	Ortho-Novum® 7/7/7 once daily, d 1-29	400 mg once daily, d 16-29	19	ethinyl estradiol: 1.15 (0.99, 1.32) norethindrone: 1.67 (1.42, 1.96)	Ethinyl estradiol: 1.48 (1.31, 1.68) norethindrone: 2.10 (1.68, 2.62)	ethinyl estradiol: 1.91 (1.57, 2.33) norethindrone: 3.62 (2.57, 5.09)
fluconazole	200 mg once daily, d 1-10 and 200 mg once daily, d 11-20	300 mg once daily/ritonavir 100 mg once daily, d 11-20	11 (d1-10) 29 (d11-20)	1.05 (0.99, 1.10)	1.08 (1.02, 1.15)	1.07 (1.00, 1.15)
methadone	stable maintenance dose, d 1-15	400 mg once daily d 2-15	16	(R)-methadone ^d 0.91 (0.84, 1.0) total: 0.85 (0.78, 0.93)	(R)-methadone ^d 1.03 (0.95, 1.10) total: 0.94 (0.87, 1.02)	(R)-methadone ^d 1.11 (1.02, 1.20) total: 1.02 (0.93, 1.12)

nevirapine ^{e,f}	200 mg BID, d 1–23	300 mg once daily/ ritonavir 100 mg once daily, d 4–13, then 400 mg once daily/ ritonavir 100 mg once daily, d 14–23	23	1.17 (1.09, 1.25)	1.25 (1.17, 1.34)	1.32 (1.22, 1.43)
		400 mg once daily/ ritonavir 100 mg once daily, d 14–23		1.21 (1.11, 1.32)	1.26 (1.17, 1.36)	1.35 (1.25, 1.47)
omeprazole ^g	40 mg single dose d 7 and d 20	400 mg once daily d 1-12	16	1.24 (1.04, 1.47)	1.45 (1.20, 1.76)	N/A
rifabutin	300 mg once daily, d 1-10 then 150 mg once daily, d 11-20	600 mg once daily ^h , d 11-20	3	1.18 (0.94, 1.48)	2.10 (1.57, 2.79)	3.43 (1.98, 5.96)
				25-O- desacetyl- rifabutin: 8.20 (5.90, 11.40)	25-O- desacetyl- rifabutin: 22.01 (15.97, 30.34)	25-O- desacetyl- rifabutin: 75.6 (30.1, 190.0)
rosiglitazone ⁱ	4 mg single dose, d 1, 7, 17	400 mg once daily d 2-7, then 300 mg once daily/ ritonavir 100 mg once daily, d 8-17	14	1.08 (1.03, 1.13)	1.35 (1.26, 1.44)	NA
		300 mg once daily/ ritonavir 100 mg once daily, d 8-17		0.97 (0.91, 1.04)	0.83 (0.77, 0.89)	NA
saquinavir (soft gelatin capsule) ^j	1200 mg once daily, d 1-13	400 mg once daily, d 7-13	7	4.39 (3.24, 5.95)	5.49 (4.04, 7.47)	6.86 (5.29, 8.91)
tenofovir ^k	300 mg once daily with food d 9-16 and d 24-30	400 mg once daily with food d 2-16	33	1.14 (1.08, 1.20)	1.24 (1.21, 1.28)	1.22 (1.15, 1.30)
		300 mg once daily, d 1-7 (pm) d25-34 (pm) ^k	300 mg once daily/ritonavir 100 mg once daily, d 25-34 (am) ^k	14 (d1-7) 12 (d25-34)	1.34 (1.20, 1.51)	1.37 (1.30, 1.45)
voriconazole ^l (subjects with at least one functional CYP2C19 allele)	200 mg BID, d 2-3, 22-30;	300 mg/ritonavir 100 mg QD, d 11- 30	20	0.90 (0.78, 1.04)	0.67 (0.58, 0.78)	0.61 (0.51, 0.72)
	400 mg BID, d 1, 21					
voriconazole ^l (subjects without a functional CYP2C19 allele)	50 mg BID, d 2-3, 22-30;	300 mg/ritonavir 100 mg QD, d 11- 30	8	4.38 (3.55, 5.39)	5.61 (4.51, 6.99)	7.65 (5.71, 10.2)
	100 mg BID, d 1, 21					

lamivudine + zidovudine	150 mg lamivudine + 300 mg zidovudine BID, d 1-12	400 mg once daily, d 7-12	19	lamivudine: 1.04 (0.92, 1.16)	lamivudine: 1.03 (0.98, 1.08)	lamivudine: 1.12 (1.04, 1.21)
				zidovudine: 1.05 (0.88, 1.24)	zidovudine: 1.05 (0.96, 1.14)	zidovudine: 0.69 (0.57, 0.84)
				zidovudine glucuronide: 0.95 (0.88, 1.02)	zidovudine glucuronide: 1.00 (0.97, 1.03)	zidovudine glucuronide: 0.82 (0.62, 1.08)

- Data provided are under fed conditions unless otherwise noted.
- All medicines were given under fasted conditions.
- 400 mg didanosine enteric-coated capsules and atazanavir were administered together with food on Days 8 and 19.
- (R)-methadone is the active isomer of methadone.
- Study was conducted in HIV-infected individuals.
- Subjects were treated with nevirapine prior to study entry.
- Omeprazole was used as a metabolic probe for CYP2C19. Omeprazole was given 2 hours after atazanavir on Day 7, and was given alone 2 hours after a light meal on Day 20.
- Not the recommended therapeutic dose of atazanavir.
- Rosiglitazone used as a probe substrate for CYP2C8.
- The combination of atazanavir and saquinavir 1200 mg once daily produced daily saquinavir exposures similar to the values produced by the standard therapeutic dosing of saquinavir at 1200 mg TID. However, the C_{max} is about 79% higher than that for the standard dosing of saquinavir (soft gelatin capsules) alone at 1200 mg TID.
- Administration of tenofovir disoproxil fumarate and atazanavir was temporally separated by 12 hours.
- Refer also to Table 3 (see section 4.5)

AUC = area under the [concentration-time] curve; BID = twice daily; C_{max} = maximum plasma concentration; C_{min} = minimum plasma concentration; d = day; h = hour; mg = milligram; n = number; NA = not available.

Effects on Electrocardiogram

Concentration- and dose-dependent prolongation of the PR interval in the electrocardiogram has been observed in healthy volunteers receiving atazanavir in a clinical pharmacology study (study 076), in which oral doses of 400 mg and 800 mg were compared with placebo in 72 healthy subjects. The mean (\pm SD) maximum change in PR interval from the predose value was 24 (\pm 15) msec following oral dosing with 400 mg of atazanavir (n=65) and 60 (\pm 25) msec following oral dosing with 800 mg of atazanavir (n=65) compared to 13 (\pm 11) msec following dosing with placebo (n=67). The PR interval prolongations in this study were asymptomatic. There is limited information on the potential for a pharmacodynamic interaction in humans between atazanavir and other medicines that prolong the PR interval of the electrocardiogram (see section 4.4). In the placebo-controlled study 076, there was no concentration-dependent effect of atazanavir on the QTc interval (using Fridericia's correction). For HIV-infected patients in study 045 treated with atazanavir + ritonavir, atazanavir + saquinavir, or lopinavir + ritonavir, each with tenofovir and an NRTI (see section 5.1), no female patients had a QTc interval >470 msec and two male patients has a QTc interval of 450-500 msec. No patients receiving atazanavir + ritonavir, 2 (2%) patients receiving atazanavir + saquinavir, and 1 (<1%) patient receiving lopinavir + ritonavir had an on-study change in QTc > 60 msec. No atazanavir-treated healthy subject or HIV-infected patient had a QTc interval > 500 msec.

5.3 Preclinical safety data

Genotoxicity

Atazanavir was negative in reverse-mutation assays in bacteria and in *in vivo* micronucleus and *ex vivo* DNA repair tests in rats. In an *in vitro* primary human lymphocyte cytogenetic assay, atazanavir increased the frequency of chromosome aberrations at cytotoxic concentrations in the absence and presence of metabolic activation. However, atazanavir did not induce chromosome aberrations in the absence and presence of metabolic activation at concentrations that were approximately 3 and 22 times the C_{max} , respectively, and 12 and 98 times the average steady-state concentration, respectively, in humans given the recommended dose. In *in vivo* studies in rats,

atazanavir did not induce micronuclei in bone marrow, DNA damage in duodenum (comet assay), or unscheduled DNA repair in liver at plasma and tissue concentrations exceeding those that were clastogenic *in vitro*.

Carcinogenesis and mutagenesis

Carcinogenicity studies with atazanavir were conducted in mice and rats. Mice were administered doses of 20, 40, and 80 mg/kg/day in males and 40, 120, and 360 mg/kg/day in females. In female mice, there was an increase in the incidences of benign hepatocellular adenomas at the highest dose. The exposure in female mice at the high dose is approximately seven times exposure in humans given atazanavir 400 mg once daily. No increase in the incidence of tumors was observed in female mice at nontumorigenic doses or male mice at any dose. Exposures in male and female mice at nontumorigenic doses are approximately four times human exposure at 400 mg/day. In rats administered doses of 100, 350, and 1200 mg/kg/day, there was no increased incidence of any tumor type. Exposures in rats at the highest dose are approximately two (males) and six (females) times the exposure in humans given atazanavir 400 mg daily. The increased incidence of benign hepatic adenomas in high-dose female mice was likely the result of increased hepatocellular proliferation secondary to cytotoxic liver changes (single-cell necrosis) and is considered unlikely to have clinical relevance at human therapeutic exposures.

6. Pharmaceutical Particulars

6.1 List of excipients

Atazanavir Viartis capsules also contains

- lactose
- crospovidone
- magnesium stearate.

The capsule shells contain gelatin and titanium dioxide and marked with black printing ink. The capsules have the following colourants:

- 150 mg – iron oxide red, patent blue V
- 200 mg – iron oxide yellow, indigo carmine, patent blue V
- 300 mg – iron oxide yellow, iron oxide red, patient blue V

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 months.

6.4 Special precautions for storage

Store at or below 25°C.

6.5 Nature and contents of container

HDPE bottle packs, containing 60 tablets, with a child-resistant closure.

PVC/PVdC-Al blister packs, containing 60 tablets.

Not all strengths or pack types may be marketed.

6.6 Special precautions for disposal

No special requirements for disposal.

7. Medicines Schedule

Prescription Medicine

8. Sponsor Details

Viatrix Ltd
PO Box 11-183
Ellerslie
AUCKLAND
www.viatrix.co.nz
Telephone 0800 168 169

9. Date of First Approval

21 December 2017

10. Date of Revision of the Text

28 March 2024

Summary table of changes

Section	Summary of new information
2	Updated excipient with known effect Addition of allergen declaration
2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.3	Minor editorial changes
4.3	Addition of apalutamide and lomitapide co-administration as a contraindication. Clarification contraindication is with orally administered midazolam.
4.4	Information in use in elderly and laboratory tests
4.5	Information on interactions with apalutamide, other lipid-modifying agents: lomitapide, betrixaban, edoxaban, antiplatelet medications, antineoplastic medications, elagolix, fostamatinib, dexamethasone and other corticosteroids. Editorial changes to Table 2
4.6	Updated information on use in pregnancy and affect on fertility
4.8	Updated Table 4 and 9 Updated ADR reporting website
5.1 & 5.2	Addition of 48 week clinical study results

	Updated Table 14, 19, 20, and 21
6.1	Removal of allergen declaration